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Abstract (S)-blebbistatin is a widely used research tool to study myosin II, an important 
regulator of many motility based diseases. Its potency is too low to be of clinical relevance, 
but identification of analogs with enhanced potency could deliver leads for targeted 
pharmacotherapeutics. This, however, requires a profound insight into the structure-activity 
relationship of the (S)-blebbistatin scaffold. Therefore, new D-ring modified (S)-blebbistatin 
derivatives were prepared to extend the existing small library of analogs. These molecules 
were obtained via an improved synthesis pathway and their myosin II inhibitory properties 
were evaluated in vitro. Finally, all new and known D-ring modified (S)-blebbistatin analogs 
were compared and the most potent ones underwent a screening of their physicochemical 
properties.   
Keywords blebbistatin, myosin II, photostability, solubility, cell membrane permeability 
Abbreviations 2-mTHF (2-methyltetrahydrofuran); A-B (apical-to-basolateral); B-A 
(basolateral-to-apical); CV (column volume); DMAP (4-dimethylaminopyridine); DMEM 
(Dulbecco’s modified Eagle medium); EGTA (ethylene glycol-bis(β-aminoethyl ether)-
N,N,N’,N’-tetraacetic acid); GFP (green fluorescent protein); HBSS (Hank’s balanced salt 
solution); HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); MOE (molecular 
operating environment); N.D. (not determined); Papp (apparent permeability); PBS 
(phosphate-buffered saline); s.d. (standard deviation); t1/2 (photodegradation half-life); TBAB 
(tetra-n-butylammonium bromide) 
2 
 
1. Introduction 
Myosins are actin-based molecular motors of the cell that convert the energy released by ATP 
hydrolysis into force and movement in an ATPase cycle [1]. Myosin II is part of the complex 
cellular processes driving cell division and cell movement. In recent years, interest in the role 
of myosin II in aberrant cellular function has strongly grown [2]. It has been identified as an 
important regulator in motility based diseases, e.g. viral infections [3–6], bacterial infections 
[7] and invasion in malignant disease [8–14]. The central role of myosin II in these diseases 
was revealed with the aid of the small-molecule research tool (S)-blebbistatin (S)-1. This 
molecule is the best known probe for myosin II: it is a micromolar, cell membrane permeable, 
uncompetitive inhibitor of the protein’s ATPase activity [15]. (S)-blebbistatin (S)-1 is an 
important research tool, but it carries a number of physicochemical deficiencies (e.g. 
photosensitivity upon blue light irradiation, low water solubility and ensuing interference of 
precipitates in read-outs) and improved analogs have been proposed in this context [16–19]. 
Novel myosin II inhibitors with significantly enhanced potency could also have the potential 
to serve as leads for targeted pharmacotherapeutics. Thus, new (S)-blebbistatin derivatives are 
necessary to provide supplemental information to the hitherto established structure-activity 
relationships [16–21].  
Analysis of the co-crystal structure of (S)-blebbistatin (S)-1 bound to the metastable state of 
Dictyostelium discoideum myosin II (PDB: 1YV3) [22] indicated that space for extra 
(hydrophobic) substituents is present in the binding pocket surrounding ring D, in particular 
near the 3’- and 4’-positions (Figure 1). We therefore investigated the tolerance of: (i) 
substituents of varying size in the 3’-position, ranging from allyloxy in analog (S)-2 to 
diallylamino in compound (S)-7, (ii) ring fusion at the 3’,4’-position, with a conformationally 
restrained monofunctionalized 3’-amino group in indoline (S)-8, a lipophilic naphthyl group 
incorporated in structure (S)-9 and a more polar indole in analog (S)-10 and (iii) functional 
groups of varying size in the 4’-position, i.e. hydroxy, allyloxy and benzyloxy (derivatives 
(S)-11–13) (Figure 2).  
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Figure 1. (A) Binding mode of (S)-blebbistatin (S)-1 (orange) with Dictyostelium discoideum 
myosin II (PDB structure: 1YV3) [22]. (B) Predicted binding poses of molecules (S)-5 (cyan), 
(S)-7 (yellow) and (S)-10 (fuchsia). (C) Predicted binding poses of compounds (S)-9 (white), 
(S)-12 (cyan) and (S)-13 (yellow). Interaction surfaces (onset of Van der Waals clash) are 
shown: pink indicates polar areas on the receptor surface, green indicates greasy areas. 
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Figure 2. Overview of the state of the art and present work regarding structure-activity 
relationships on the blebbistatin scaffold. Top: Overview of existing A-ring and D-ring 
modified (S)-blebbistatin derivatives [16–21]. Bottom: Overview of newly synthesized (S)-
blebbistatin derivatives (S)-2–13 with a modified D-ring.  
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2. Results and discussion 
2.1. Chemistry 
The synthesis of (S)-3’-allyloxyblebbistatin (S)-2, (S)-3’-diallylaminoblebbistatin (S)-7, (S)-
3’-hydroxyblebbistatin (S)-17 and (S)-3’-aminoblebbistatin (S)-18 has been reported 
previously by us (Scheme 1) [19]. In that sequence, amidines 14a–c underwent intramolecular 
cyclization upon treatment with LiHMDS, resulting in isolation of quinolones 15a–c. α-
Hydroxy ketones (S)-1, (S)-2 and (S)-7 were synthesized via deprotonation of quinolones 
15a–c using LiHMDS and Davis’ oxaziridine methodology. Allyl deprotection of enantiopure 
(S)-3’-allyloxyblebbistatin (S)-2 and (S)-3’-diallylaminoblebbistatin (S)-7 afforded (S)-3’-
hydroxyblebbistatin (S)-17 and (S)-3’-aminoblebbistatin (S)-18, respectively. 
 
Scheme 1. Synthesis of (S)-3’-allyloxyblebbistatin (S)-2, (S)-3’-diallylaminoblebbistatin (S)-
7, (S)-3’-hydroxyblebbistatin (S)-17 and (S)-3’-aminoblebbistatin (S)-18, as previously 
reported by Verhasselt et al. [19]. Reagents and conditions: (a) LiHMDS, THF, 0 °C, 1 h; (b) 
(1) LiHMDS, THF, −78 °C, 30 min, (2) 16, THF, −15 °C, 16 h; (c) (1) LiHMDS, THF, 0 °C, 
1.5 h, (2) 16, THF, −15 °C, 16 h; (d) Pd(PPh3)4, K2CO3, MeOH, 50 °C, 1 h; (e) N,N’-
dimethylbarbituric acid, Pd(PPh3)4, CH2Cl2, reflux, 1 h. 
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We have meanwhile developed a more convenient one-pot synthesis of α-hydroxy ketones 
from amidines, without isolation of the intermediate quinolones (Scheme 1). In this way, 
amidine 14a was converted to α-hydroxy ketone (S)-1 (step (c)) in higher yield (quant vs 
83%) and enantiomeric excess (86% vs 75%) than the two-pot procedure. This is an important 
enhancement of the synthesis of the blebbistatin scaffold. 
(S)-3’-hydroxyblebbistatin (S)-17 and (S)-3’-aminoblebbistatin (S)-18 were used as starting 
points for the synthesis of derivatives (S)-3, (S)-4, (S)-5 and (S)-6 (Scheme 2). Selective 
esterification of phenol (S)-17 (step (a)) was obtained by using stoichiometric amounts of 
Cs2CO3 and a small excess of acryloyl chloride or propionyl chloride, resulting in (S)-3’-
acryloxyblebbistatin (S)-3 (61%, ee >99%) and (S)-3’-propionyloxyblebbistatin (S)-4 (99%, 
ee 99%), respectively. (S)-3’-acrylamidoblebbistatin (S)-5 (73%, ee 99%) and (S)-3’-
propionylamidoblebbistatin (S)-6 (91%, ee >99%) were prepared through a procedure adopted 
from Jahani et al. [23]. Selective monoamidation of aniline (S)-18 (step (b)) was achieved 
using stoichiometric amounts of acrylic [24] or propionic anhydride and guanidine 
hydrochloride. In both sequences, reactions conducted with acryloyl reagents required 
chromatographic purification, thereby lowering the isolated yields.  
a a
 
Scheme 2. Synthesis of (S)-3’-acryloxyblebbistatin (S)-3, (S)-3’-propionyloxyblebbistatin (S)-
4,  (S)-3’-acrylamidoblebbistatin (S)-5 and (S)-3’-propionylamidoblebbistatin (S)-6 via 
selective esterification of phenol (S)-17 and selective mono-amidation of aniline (S)-18, 
respectively. Reagents and conditions: (a) Cs2CO3, DMAP, acryloyl chloride (for (S)-3) or 
propionyl chloride (for (S)-4), CH3CN, rt, 30 min; (b) guanidine hydrochloride, acrylic 
anhydride (for (S)-5) or propionic anhydride (for (S)-6), EtOH, 40 °C, 30 min. 
a
 Determination of ee via chiral HPLC analysis was performed after synthesis of analytical 
amounts of the (R)-enantiomers (i.e. (R)-3–6) from (R)-17–18. 
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The synthesis of (S)-benzo[c’]blebbistatin (S)-9 was performed using 2-bromonaphthalene 
(19) as starting material (Scheme 3). CuI catalyzed N-arylation of 2-pyrrolidinone (20) with 
tris(3,5-dimethyl-1H-pyrazol-1-yl)methane [25,26] and K2CO3 [27,28] as a ligand and base, 
respectively, only gave trace amounts of pyrrolidinone 21a. In contrast, use of 
N,N’-dimethylethylenediamine and K2CO3 provided pyrrolidinone 21a in excellent yield (step 
(a), 98%). Amidine 14d was obtained in moderate yield (step (b), 48%), which was 
completely converted to α-hydroxy ketone (S)-9 through our improved two-step one-pot 
procedure (step (c), 50%, ee 72%). Isolation of compound (S)-9 by acid-base extraction 
proved more difficult than for (S)-1 due to its more hydrophobic nature, resulting in a 
moderate yield. Recrystallization from CH3CN afforded enantiopure (S)- 
benzo[c’]blebbistatin (S)-9 (ee >99%).  
 
Scheme 3. Synthesis of (S)-benzo[c’]blebbistatin (S)-9. Reagents and conditions: (a) CuI, 
N,N’-dimethylethylenediamine, 20, K2CO3, 1,4-dioxane, reflux, 31 h; (b) (1) POCl3, CH2Cl2, 
rt, 24 h, (2) 22, CH2Cl2, 35 °C, 24 h; (c) (1) LiHMDS, THF, 0 °C, 1.5 h, (2) 16, THF, −15 °C, 
16 h. a The reaction mixture initially consisted of 36 mol% of 21a and 64 mol% of 14d. 
b Determination of ee via chiral HPLC analysis. c After recrystallization from CH3CN. 
Preparation of (S)-2,3-dihydro-1H-pyrrolo[2,3-c’]blebbistatin (S)-8 and (S)-1H-pyrrolo[2,3-
c’]blebbistatin (S)-10 started from 6-bromoindole (23) (Scheme 4), which was selectively 
protected to yield allylated indole 24 (step (a), 99%) [29]. The feasibility to remove the allyl 
protecting group from the indole moiety was tested using a first generation Grubbs’ carbene 
catalyst [30], but this attempt failed. As successful allyl deprotection of aliphatic amines had 
been reported previously by us [19], we opted to reduce allylated indole 24 to indoline 19b 
(step (b), 80%) [29] and reoxidize it further down the line. Pyrrolidinone 21b was synthesized 
from indoline 19b with N,N’-dimethylethylenediamine and K2CO3 (step (c), 99%). Next, the 
amidine 14e synthesis proved difficult (step (d), 42%) due to the electron withdrawing amino 
group (protonated under the reaction conditions used) present on the aryl amide. Subsequent 
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one-pot intramolecular ring closure and enantioselective hydroxylation (step (e), 51%, ee 
80%) afforded a mixture containing 86% of compound (S)-25 and 14% of oxidation product 
(S)-26, which was not the result of oxidized impurities present in the starting material. The 
moderate yield was caused by the tough isolation via acid-base extraction. Recrystallization 
from CH3CN resulted in an enantiopure mixture (ee >99%) containing 91% of (S)-25 and 9% 
of (S)-26. This mixture was used for the synthesis of (S)-2,3-dihydro-1H-pyrrolo[2,3-
c’]blebbistatin (S)-8 (step (f), 73%, ee >99%), which was separated from the unreacted (S)-26 
via chromatography. Finally, oxidation of intermediate (S)-8 with MnO2 yielded (S)-1H-
pyrrolo[2,3-c’]blebbistatin (S)-10 (step (g), 70%, ee >99%). 
 
Scheme 4. Synthesis of (S)-2,3-dihydro-1H-pyrrolo[2,3-c’]blebbistatin (S)-8 and (S)-1H-
pyrrolo[2,3-c’]blebbistatin (S)-10. Reagents and conditions: (a) (1) NaH, DMF, 0 °C, 30 min, 
(2) allyl bromide, DMF, rt, 30 min; (b) NaCNBH3, glacial acetic acid, rt, 4.5 h; (c) CuI, N,N’-
dimethylethylenediamine, 20, K2CO3, 1,4-dioxane, reflux, 33 h; (d) (1) POCl3, CH2Cl2, rt, 
24 h, (2) 22, CH2Cl2, 35 °C, 48 h; (e) (1) LiHMDS, THF, 0 °C, 2 h, (2) 16, THF, −15 °C, 
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16 h; (f) N,N’-dimethylbarbituric acid, Pd(PPh3)4, CH2Cl2, reflux, 1 h; (g) MnO2, CHCl3, rt, 
3 h. a The reaction mixture initially consisted of 37 mol% of 21b and 63 mol% of 14e. 
b
 Determination of ee via chiral HPLC analysis by comparison of (R)-enantiomer enriched 
fractions. cAfter recrystallization from CH3CN. 
(S)-4’-Allyloxyblebbistatin (S)-12 was prepared from 4-iodophenol (27) by allyl protection 
(step (a), quant) [31], N-arylation of 2-pyrrolidinone (20) (step (b), 75%) and amidine 14f 
synthesis (step (c), 78%) (Scheme 5). Amidine 14f was completely converted to α-hydroxy 
ketone (S)-12, using our improved two-step one-pot procedure, but was isolated in a moderate 
yield (step (d), 43%, ee 82%). A single recrystallization from CH3CN and subsequent allyl 
deprotection afforded enantiopure (S)-4’-allyloxyblebbistatin (S)-12 (ee >99%) and (S)-4’-
hydroxyblebbistatin (S)-11 (step (e), 77%, ee >99%), respectively. The latter was further 
modified with benzyl bromide, delivering (S)-4’-benzyloxyblebbistatin (S)-13 (step (f), 62%, 
ee >99%). 
 
Scheme 5. Synthesis of (S)-4’-allyloxyblebbistatin (S)-12, (S)-4’-hydroxyblebbistatin (S)-11 
and (S)-4’-benzyloxyblebbistatin (S)-13. Reagents and conditions: (a) TBAB, allyl bromide, 
25% aq NaOH/2-mTHF (3:2), reflux, 30 min; (b) CuI, 20, tris(3,5-dimethyl-1H-pyrazol-1-
yl)methane, K3PO4, 1,4-dioxane, reflux, 24 h; (c) (1) POCl3, CH2Cl2, rt, 24 h, (2) 22, CH2Cl2, 
35 °C, 24 h; (d) (1) LiHMDS, THF, 0 °C, 1.5 h, (2) 16, THF, −15 °C, 16 h; (e) Pd(PPh3)4, 
K2CO3, MeOH, 50 °C, 1.5 h; (f) NaI, Cs2CO3, benzyl bromide, CH3CN, 50 °C, 1 h. 
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a
 Determination of ee via chiral HPLC analysis by comparison with (R)-enantiomer enriched 
fractions. b After recrystallization from CH3CN. c Ee derived from ee of (S)-13. d The reaction 
mixture initially consisted of 94 mol% of (S)-13 and 6 mol% of dibenzylated product. 
In order to compare the newly synthesized (S)-blebbistatin derivatives with existing literature 
compounds, the synthesis of (S)-4’-nitroblebbistatin (S)-29 and (S)-4’-aminoblebbistatin (S)-
31 was also performed. Preparation of (S)-4’-nitroblebbistatin (S)-29 via direct nitration of 
(S)-blebbistatin (S)-1 resulted in a complex mixture (Scheme 6, step (a)), so we opted to 
prepare it starting from pyrrolidinone 21d, as reported by Képiró et al. [17]. In our hands, 
synthesis of the latter by nitration of N-phenylpyrrolidin-2-one was not selective: a mixture of 
70% of 4’-nitrated, 10% of 2’-nitrated and 20% of 2’,4’-dinitrated material was obtained, 
which proved difficult to purify. However, pyrrolidinone 21d could be synthesized from 1-
bromo-4-nitrobenzene (19c) and 2-pyrrolidinone (20) in excellent yield (step (b), 95%). As 
observed by Képiró et al. [17], formation of amidine 14g was difficult due to the highly 
electron withdrawing nitro group (step (c), 20%). Intramolecular ring closure upon treatment 
with LiHMDS was accompanied by production of dimer 30 (step (d) (1)), a side-reaction 
which was never observed before with other derivatives. Nevertheless, we were able to 
increase the yield of (S)-4’-nitroblebbistatin (S)-29 from previously reported 11% [17] to 38% 
via our improved one-pot intramolecular ring closure and enantioselective hydroxylation (step 
(d), 38%, ee 82%). Enantiopure (S)-4’-nitroblebbistatin (S)-29 was obtained after 
recrystallization from CH3CN (ee >99%). Reduction of the nitro group, using 10 equivalents 
of ammonium formate, resulted in a conversion of 50% and the isolation of (S)-4’-
aminoblebbistatin (S)-31 in 31% yield. 
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Scheme 6. Synthesis of (S)-4’-nitroblebbistatin (S)-29 and (S)-4’-aminoblebbistatin (S)-31. 
Reagents and conditions: (a) HNO3, H2SO4, 0 °C, 30 min; (b) CuI, N,N’-
dimethylethylenediamine, 20, K2CO3, 1,4-dioxane, reflux, 18 h; (c) (1) POCl3, CH2Cl2, rt, 
24 h, (2) 22, CH2Cl2, 35 °C, 4 days; (d) (1) LiHMDS, THF, 0 °C, 1 h, (2) 16, THF, −15 °C, 
16 h; (e) ammonium formate, Pd/C, MeOH, rt, 15 min. a The reaction mixture initially 
consisted of 80 mol% of 21d and 20 mol% of 14g. b 41% and 59% of 14g was converted to 
(S)-29 and 30, respectively. c Determination of ee via chiral HPLC analysis. d After 
recrystallization from CH3CN. e The reaction mixture initially consisted of 50 mol% of (S)-29 
and 50 mol% of (S)-31. 
2.2. Biochemical evaluation 
The newly synthesized (S)-blebbistatin derivatives (S)-2–13 and literature analogs (S)-29 and 
(S)-31 were evaluated in vitro for their myosin II inhibitory potency in a steady-state ATPase 
assay using rabbit skeletal muscle myosin II. In these studies, (S)-blebbistatin (S)-1 was used 
as a benchmark. Dose-response curves are presented in Figure 3 and Figure S1 in the 
Supporting Information. The half-maximum inhibitory concentrations (IC50) and potencies 
relative to (S)-1, expressed as the ratio of the IC50 of (S)-1 to the compound IC50, are 
summarized in Table 1.  
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Figure 3. Overview of the myosin II inhibitory properties of compounds (S)-2–13, evaluated 
in an ATPase assay with rabbit skeletal muscle myosin II. Examples of dose-response curves 
and 4-parameter logistic curve fitting obtained for (A) (S)-3’-allyloxyblebbistatin (S)-2, (S)-
3’-acryloxyblebbistatin (S)-3 and (S)-3’-propionyloxyblebbistatin (S)-4, (B) (S)-3’-
acrylamidoblebbistatin (S)-5, (S)-3’-propionylamidoblebbistatin (S)-6 and (S)-3’-
diallylaminoblebbistatin (S)-7, (C) (S)-2,3-dihydro-1H-pyrrolo[2,3-c’]blebbistatin (S)-8, (S)-
benzo[c’]blebbistatin (S)-9 and (S)-1H-pyrrolo[2,3-c’]blebbistatin (S)-10 and (D) (S)-4’-
hydroxyblebbistatin (S)-11, (S)-4’-allyloxyblebbistatin (S)-12 and (S)-4’-
benzyloxyblebbistatin (S)-13. Data points represent the mean ± s.d. of at least three samples 
(N = 1). (S)-blebbistatin (S)-1 is shown as a benchmark. Compound concentrations exceeding 
10.8 µM, 100 µM and 50 µM resulted in precipitation of (S)-2, (S)-3 and (S)-4, respectively, 
in the assay buffer. As an approximation, the relative ATPase activity obtained for (S)-
blebbistatin (S)-1 at a concentration of 32.5 µM was used to set the lower asymptote of the 
fitted curve for these compounds.  
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Table 1. Evaluation of the myosin II inhibitory properties of compounds (S)-1–13: half-
maximum inhibitory concentrations (IC50) for the steady-state ATPase activity of rabbit 
skeletal muscle myosin II.a,b 
Compound IC50 
(µM) 
Relative potency 
to (S)-1
 
Compound IC50 
(µM) 
Relative potency 
to (S)-1
 
(S)-1 2.16 ± 0.14 1.0 ± 0.1 (S)-1 0.873 ± 0.114 1.0 ± 0.2 
(S)-2 9.41 ± 1.83 0.23 ± 0.05 (S)-8 7.70 ± 0.19 0.11 ± 0.02 
(S)-3 57.6 ± 7.8 0.04 ± 0.01 (S)-9 >40e <0.02  
(S)-4 23.5 ± 2.5 0.09 ± 0.01 (S)-10 7.20 ± 0.59 0.12 ± 0.02 
(S)-5 >100c <0.02 (S)-11 5.47 ± 1.32 0.16 ± 0.04 
(S)-6 >100c <0.02 (S)-12 0.380 ± 0.003 2.3 ± 0.3 
(S)-7 >10.8d - (S)-13 >40e <0.02 
a
 Compounds (S)-2–7 and (S)-8–13 were evaluated with a different batch of rabbit skeletal 
muscle myosin II, resulting in a different protein activity. In both series, this deviation was 
accounted for by expressing the IC50 of each compound relative to the respective IC50 of (S)-
1. b Data represent the mean ± s.d. of two independent experiments. c Highest compound 
concentration used was 100 µM. d Highest compound concentration used was 10.8 µM, as 
concentrations higher than 10.8 µM resulted in compound precipitation in the assay buffer. 
e
 Highest compound concentration used was 40 µM. 
From these and literature data [19], some patterns can be recognized regarding the influence 
of substitution on myosin II inhibitory activity (presented as relative potency to (S)-1 in Table 
2). First, small groups are equally well tolerated in the 4’-position as in the 3’-position ((S)-11 
and (S)-31 vs (S)-17 and (S)-18, respectively). However, for medium-sized groups, 4’-
substitution of ring D is preferred over 3’-substitution ((S)-12 vs (S)-2). Finally, large 
substituents ((S)-33, (S)-34, (S)-9, (S)-5, (S)-6 and (S)-13) are not compatible with the binding 
pocket, at either position.  
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Table 2. Overview of present and literature data of the rabbit skeletal muscle myosin II 
inhibitory properties of compounds (S)-1–13, 17, 18, 29, 31–34, expressed as the relative 
potency to (S)-1.a,b 
Compound Relative potency to (S)-1 Compound
 
Relative potency to 
(S)-1 
Parent compound 
 
1.0 ± 0.2 
  
Small substituents 
 
0.16 ± 0.04 
 
0.11 ± 0.01 [19]  
 
0.19 ± 0.01 
 
0.15 ± 0.01 [19]  
Medium-sized substituents 
 
0.04 ± 0.01c [19] 
 
2.5 ± 0.2 
 
0.12 ± 0.02 
 
0.11 ± 0.02 
 
2.3 ± 0.3 
 
0.23 ± 0.05 
Large substituents 
 
<0.02 [19] 
 
<0.02 [19] 
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Compound Relative potency to (S)-1 Compound
 
Relative potency to 
(S)-1 
 
<0.02 
 
0.04 ± 0.01 
 
0.09 ± 0.01 
 
<0.02 
 
<0.02 
 
<0.02 
a (S)-3’-diallylaminoblebbistatin (S)-7 is not included, as compound precipitation occurred at a 
concentration of 10.8 µM. 4’-Azidoblebbistatin and 4’-chloroblebbistatin are not included, 
because no literature data are available for the rabbit skeletal muscle myosin II inhibitory 
properties of these compounds [17,20]. b Data represent the mean ± s.d. of two independent 
experiments. c Ee 84%. 
In all, these structure-activity relationships indicate that D-ring substitution does not lead to 
significant potency enhancement. However, this part of the (S)-blebbistatin scaffold can be 
used to fine-tune the physicochemical profile of the molecule, without affecting the biological 
activity in an appreciable manner. For instance, disadvantages related to the use of (S)-
blebbistatin (S)-1 as a research tool are (i) photosensitivity when using fluorescence 
microscopy with blue light irradiation (400–500 nm) to visualize GFP-labeled myosin II and 
(ii) low aqueous solubility and ensuing interference of precipitates in read-outs [19,32–40]. 
Therefore, (S)-blebbistatin (S)-1 and the most potent analogs (S)-3’-allyloxyblebbistatin (S)-2, 
(S)-4’-hydroxyblebbistatin (S)-11, (S)-4’-allyloxyblebbistatin (S)-12, (S)-3’-
hydroxyblebbistatin (S)-17, (S)-3’-aminoblebbistatin (S)-18, (S)-4’-nitroblebbistatin (S)-29 
and (S)-4’-aminoblebbistatin (S)-31 were evaluated for their photostability, water solubility 
and cell membrane permeability. 
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2.3. Photostability 
Qualitative literature data are available showing that (S)-blebbistatin (S)-1 is photodegradable 
upon blue light irradiation (400–500 nm), while (S)-4’-nitroblebbistatin (S)-29 and (S)-4’-
aminoblebbistatin (S)-31 are not [16–18,32,35,37]. However, up till now, quantification of 
this behavior is lacking. We therefore developed a suitable experimental setup to generate 
half-life curves.  
Using a fluorescence spectrometer (F900, Edingburgh Instruments) equipped with a 450 W 
Xenon Lamp, Képiró et al. reported degradation of (S)-blebbistatin (S)-1 after 5 min of 
irradiation at 480 ± 10 nm [17,18]. Initially, we applied this setup to examine the time-
dependent effect of blue light irradiation on the absorption spectrum of the latter compound. 
However, irradiating 20 µM samples of (S)-blebbistatin (S)-1 in phosphate-buffered saline 
(PBS) (containing 2.67% (v/v) methanol) for 30 min at 488 nm did not result in any 
degradation (Figure 4A). Therefore, we changed the setup and solutions of (S)-blebbistatin 
(S)-1 in DMSO and DMSO/H2O (1:1), with concentrations ranging from 100 µM to 600 µM, 
were irradiated with a fluorescent tube lamp emitting 390–470 nm with a maximum at 420 nm 
(Figure S2 in the Supporting Information) [35]. Decomposition of (S)-blebbistatin (S)-1 was 
followed up in time by HPLC. As depicted by Figure 4B and Figure S3, degradation required 
the presence of water: at all concentrations evaluated, hardly any decomposition could be 
observed when 100% DMSO was used as solvent. Figure 4C shows the dependence of (S)-
blebbistatin (S)-1 half-life on concentration, which follows a linear pattern. Illumination times 
exceeding two hours resulted in substantial evaporation of solvent, making quantification of 
degradation impossible. A concentration of 100 µM was therefore used in further experiments 
to obtain sufficient degradation within 90 min of irradiation. Finally, the photosensitivity of 
(S)-blebbistatin (S)-1 was studied in an aqueous medium that mimics the conditions of cell 
experiments, i.e. a 1:1 mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf 
serum (Figure 4D). The observed reduction in half-life (Figure 4D vs Figure 4B) indicates 
that observations made in simple aqueous media cannot be extrapolated to complex biological 
media. The stability of the (S)-blebbistatin derivatives was therefore also assessed in a 1:1 
mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf serum [41]. 
Figure 5 illustrates the decomposition of (S)-3’-allyloxyblebbistatin (S)-2, (S)-4’-
hydroxyblebbistatin (S)-11, (S)-4’-allyloxyblebbistatin (S)-12, (S)-3’-hydroxyblebbistatin (S)-
17, (S)-3’-aminoblebbistatin (S)-18, (S)-4’-nitroblebbistatin (S)-29 and (S)-4’-
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aminoblebbistatin (S)-31 in function of time and the half-life of these compounds is 
summarized in Table 3. Consistent with the observations of Képiró et al. [17], we found (S)-
4’-nitroblebbistatin (S)-29 to possess the highest stability after 90 min of irradiation. 
However, (S)-4’-aminoblebbistatin (S)-31 already started to decompose after 10 min, while 
this analog was expected to be equally stable as (S)-4’-nitroblebbistatin (S)-29 [18]. 
Nonetheless, the latter compound still had a higher half-life than (S)-blebbistatin (S)-1. On the 
contrary, (S)-3’-allyloxyblebbistatin (S)-2, (S)-3’-aminoblebbistatin (S)-18, (S)-3’-
hydroxyblebbistatin (S)-17 and (S)-4’-allyloxyblebbistatin (S)-12 displayed a similar 
resistance toward photodegradation as (S)-blebbistatin (S)-1. (S)-4’-Hydroxyblebbistatin (S)-
11 showed the lowest stability.  
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Figure 4. Investigation of photostability of (S)-blebbistatin (S)-1. (A) Absorbance spectra of 
20 µM (S)-blebbistatin (S)-1 in PBS/MeOH (97.3:2.7) after irradiation at 488 nm at the 
19 
 
indicated times. (B) Degradation of 100 µM (S)-blebbistatin (S)-1 in DMSO and DMSO/H2O 
(1:1) after irradiation at 390–470 nm (maximum at 420 nm) and 4-parameter logistic curve 
fitting (half-life is 39 min). (C) Linear increase of (S)-blebbistatin (S)-1 degradation half-life 
in function of compound concentration in DMSO/H2O (1:1) after irradiation at 390–470 nm 
(maximum at 420 nm). (D) Degradation of 100 µM (S)-blebbistatin (S)-1 in a 1:1 mixture of 
DMSO and DMEM supplemented with 20% (v/v) fetal calf serum after irradiation at 390–
470 nm (maximum at 420 nm) and 4-parameter logistic curve fitting (half-life is 14 min).  
 
Figure 5. Investigation of photostability of (S)-3’-allyloxyblebbistatin (S)-2, (S)-4’-
hydroxyblebbistatin (S)-11, (S)-4’-allyloxyblebbistatin (S)-12, (S)-3’-hydroxyblebbistatin (S)-
17, (S)-3’-aminoblebbistatin (S)-18, (S)-4’-nitroblebbistatin (S)-29 and (S)-4’-
aminoblebbistatin (S)-31 toward 390–470 nm (maximum at 420 nm) irradiation. (S)-
blebbistatin (S)-1 is shown as a benchmark and 4-parameter logistic curve fitting was 
performed for all compounds except (S)-29. Compound concentrations were 100 µM in a 1:1 
mixture of DMSO and DMEM supplemented with 20% (v/v) fetal calf serum.  
The observation that the presence of water is required to initiate degradation might question 
the correct use of the term photostability and it is tempting to speculate that a degradation 
product of water, e.g. hydroxyl or peroxy radicals, might be involved in the decay of 
(S)-blebbistatin (S)-1 and some of its derivatives. The photosensitizing ability of (S)-
blebbistatin (S)-1 and ensuing generation of oxidative conditions upon blue light illumination 
was proven by Mikulich et al. [35]. Thus, its photosensitizing properties may be sufficient to 
generate hydroxyl or peroxy radicals in an aqueous mixture upon blue light irradiation, which 
in turn are able to induce oxidative degradation of (S)-blebbistatin (S)-1. Hence, (S)-
blebbistatin (S)-1 might rather be prone to oxidative degradation than to photodegradation. 
This would explain why an analog bearing an electron withdrawing group does not 
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decompose under the applied conditions. Further experiments are required to prove this 
hypothesis (but are beyond the scope of the present report).  
Table 3. Overview of key tool properties of (S)-blebbistatin (S)-1 and analogs (S)-3’-
allyloxyblebbistatin (S)-2, (S)-4’-hydroxyblebbistatin (S)-11, (S)-4’-allyloxyblebbistatin (S)-
12, (S)-3’-hydroxyblebbistatin (S)-17, (S)-3’-aminoblebbistatin (S)-18, (S)-4’-nitroblebbistatin 
(S)-29 and (S)-4’-aminoblebbistatin (S)-31: myosin II inhibitory potency (expressed as 
relative potency to (S)-1), photostability (expressed as half-life, t1/2), steady-state aqueous 
solubility and Caco-2 apical-to-basolateral (A-B) and basolateral-to-apical (B-A) cell 
membrane permeability (expressed as apparent permeability, Papp).  
Compound 
Relative 
potency to (S)-
1a 
t1/2 
(min) 
Solubilitya,b 
 (µM) 
Pappc  
(10-6 cm s-1) 
Recoveryc 
(%) 
A-B B-A A-B B-A 
(S)-1 1.0 ± 0.2 14 6.18 ± 0.08 [19]  60.5 ± 1.8 19.2 ± 0.3 66 ± 1 66 ± 4 
(S)-2 0.23 ± 0.05 15 2.83 ± 0.09 N.D.d N.D.d N.D.d N.D.d 
(S)-11 0.16 ± 0.04 4.7 82.4 ± 9.7 N.D.d N.D.d N.D.d N.D.d 
(S)-12 2.3 ± 0.3 8.8 2.75 ± 0.05 29.7 ± 0.6 7.58 ± 0.05 32 ± 1 65 ± 1 
(S)-17 0.11 ± 0.01 [19] 11 193 ± 1 [19] 28.5 ± 0.3 17.2 ± 0.1 49 ± 1 70 ± 1 
(S)-18 0.15 ± 0.01 [19] 13 186 ± 9 [19] 62.7 ± 3.1 26.2 ± 0.1 79 ± 1 74 ± 4 
(S)-29 2.5 ± 0.2 >90e 31.7 ± 1.6 32.5 ± 1.0 2.23 ± 0.02 34 ± 1 72 ± 1 
(S)-31 0.19 ± 0.01 44 >200f 69.4 ± 3.0 31.1 ± 3.5 85 ± 1 82 ± 1 
a
 Data represent the mean ± s.d. of two independent experiments. b Steady-state solubility in 
PBS pH 7.4 buffer. c Caco-2 A-B (pH 7.4/7.4) and B-A (pH 7.4/7.4) permeability; compound 
concentrations were 20 µM. d Not determined. e Sample collected after 90 min resulted in 
33% degradation. f Highest compound concentration used was 200 µM. 
2.4. Water solubility and cell membrane permeability 
The low aqueous solubility of (S)-blebbistatin (S)-1 and its ensuing precipitates pose a 
problem for read-outs in cell-based experiments. For these settings, the ideal tool compound 
should combine a good cell membrane permeability with a high aqueous solubility. The 
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steady-state solubility of (S)-3’-allyloxyblebbistatin (S)-2, (S)-4’-hydroxyblebbistatin (S)-11, 
(S)-4’-allyloxyblebbistatin (S)-12, (S)-4’-nitroblebbistatin (S)-29 and (S)-4’-aminoblebbistatin 
(S)-31 was determined in PBS pH 7.4 buffer (2% (v/v) DMSO) and was compared with our 
previously reported data of (S)-blebbistatin (S)-1, (S)-3’-hydroxyblebbistatin (S)-17 and (S)-
3’-aminoblebbistatin (S)-18 (Table 3) [19]. As expected [18], (S)-4’-aminoblebbistatin (S)-31, 
(S)-3’-hydroxyblebbistatin (S)-17 and (S)-3’-aminoblebbistatin (S)-18 showed the highest 
water solubility, while (S)-4’-hydroxyblebbistatin (S)-11 was surprisingly less soluble than the 
latter.  
Caco-2 apical-to-basolateral (A-B) and basolateral-to-apical (B-A) cell membrane permeation 
data were also collected. All compounds evaluated showed high A-B permeability (Papp 
>20×10-6 cm s-1). Further, the high ratio of A-B to B-A permeability suggests that none of the 
compounds are substrates for efflux transporters. Compound concentrations in both donor and 
acceptor compartments were analyzed to identify potential underestimation of permeability. 
The low A-B recovery of (S)-4’-allyloxyblebbistatin (S)-12, (S)-3’-hydroxyblebbistatin (S)-17 
and (S)-4’-nitroblebbistatin (S)-29 may be attributed to retention in the cell monolayer, 
nonspecific binding onto plastic, compound precipitation or degradation during assay 
incubation. As B-A recovery is significantly higher for these molecules, the low A-B recovery 
is likely due to retention. Interestingly, comparison between (S)-blebbistatin (S)-1 and the 
highly water soluble analogs (S)-17, (S)-18 and (S)-31 revealed that the increase in aqueous 
solubility is not accompanied by a loss in cell membrane permeability. In cell-based 
screenings requiring high inhibitor concentrations and where precipitates might interfere with 
read-outs, these molecules are thus ideal substitutes for (S)-blebbistatin (S)-1. 
3. Conclusions 
Novel D-ring modified (S)-blebbistatin analogs were prepared in a shorter and higher yielding 
synthesis of the blebbistatin scaffold. This was accomplished by conducting the 
intramolecular ring closure of amidines and subsequent α-hydroxylation of the intermediate 
quinolones in a two-step one-pot procedure. In this way, together with existing literature 
compounds, a more complete library of D-ring modified (S)-blebbistatin analogs was obtained 
for thorough structure-activity and structure-property analysis. We evaluated the myosin II 
inhibitory properties of the new analogs and the literature derivatives in an ATPase assay with 
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rabbit skeletal muscle myosin II. The thus obtained SAR information revealed that large 
groups in the 3’- and/or 4’-position present potential bottlenecks for inhibitor design. In all, 
D-ring substitution does not lead to significant potency enhancement, but is useful to fine-
tune the physicochemical profile of (S)-blebbistatin (S)-1. We were able to quantify for the 
first time the photosensitivity of (S)-blebbistatin (S)-1 and confirmed that research 
applications requiring blue light irradiation are best conducted with (S)-4’-nitroblebbistatin 
(S)-29. On the other hand, when solubility issues of (S)-blebbistatin (S)-1 pose a problem for 
read-outs in cell-based experiments, (S)-3’-hydroxyblebbistatin (S)-17, (S)-3’-
aminoblebbistatin (S)-18 or (S)-4’-aminoblebbistatin (S)-31 should be used as alternatives. 
These compounds combine a 30-fold higher aqueous solubility with conservation of cell 
membrane permeability. From an economical point of view, (S)-3’-hydroxyblebbistatin (S)-17 
is the best choice for these applications, as it is the most readily accessible. 
4. Materials and methods 
4.1. In silico studies 
All in silico studies were performed using Molecular Operating Environment (MOE) 2015.10 
(Chemical Computing Group) as molecular modelling software [42]. Analyses were 
conducted based on the co-crystal structure of Dictyostelium discoideum myosin II heavy 
chain and blebbistatin (PDB: 1YV3) [22]. Automated structure preparation was performed 
using standard parameters. Partial charges were automatically calculated. Minimizations were 
performed using an RMSD gradient of 0.001 Kcal mol-1 Å-1 and the AMBER99 force field. 
4.2. Chemistry 
4.2.1. General 
 
Dichloromethane was dried by heating under reflux over CaH2 and distilled under an 
atmosphere of nitrogen. Tetrahydrofuran was dried by heating under reflux with 
sodium/benzophenone under a nitrogen atmosphere and collected by distillation. Dry 1,4-
dioxane was purchased from Sigma-Aldrich. Dry acetonitrile, dry methanol and dry 
N,N-dimethylformamide were purchased from Acros Organics. Reagents were purchased at 
the highest commercial quality and were used as received without further purification.  
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Yields refer to chromatographically and spectroscopically (1H NMR) homogeneous material, 
unless otherwise stated. 
Reactions were monitored on an Agilent 1200 series HPLC system fitted with an Ascentis® 
Express C18-column (2.7 µm particle size, 4.6 mm internal diameter), using acetonitrile/water 
(5 mM NH4OAc) as eluent. Low-resolution mass spectra were recorded on an Agilent 1100 
series VL mass spectrometer (ESI, 70 eV). High-resolution mass spectra (HRMS) were 
recorded using an Agilent Technologies 6210 series time-of-flight (TOF) or Thermo 
Scientific MAT95XP-Trap mass spectrometer. Thin layer chromatography (TLC) was carried 
out on 0.25 mm Merck silica plates (60 F254) and spots were visualized by UV light (254 nm). 
Flash column chromatography was performed on an automated Reveleris® X1 flash 
chromatography system, using Reveleris® C18 or Reveleris® silica cartridges. Melting points 
were determined using a Wagner & Munz WME Heizbank Kofler bench. 
NMR spectra were recorded on a Bruker Avance III instrument. 1H NMR (400 MHz) 
chemical shifts are recorded in CDCl3, DMSO-d6 or CD3OD, reported in ppm and measured 
relative to tetramethylsilane or the residual undeuterated solvent as the internal reference, 
respectively. 13C NMR (100.6 MHz) chemical shifts are reported in ppm and were measured 
relative to the residual solvent as the internal reference. The following abbreviations were 
used to explain NMR peak multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, 
p = pentet, m = multiplet, br = broad. 
Infrared spectroscopy was performed on a Shimadzu IRAFFINITY-1S WL spectrophotometer 
with an ATR (Attenuated Total Reflectance) accessory. Samples were analyzed in neat form 
and selected peaks are reported.  
The enantiomeric excess (ee) of chiral compounds was determined via chiral HPLC analysis 
using a Daicel Chiralpak IA column (5 µm particle size, 150 mm length, 2.1 mm internal 
diameter). Detection wavelength was set at 268 nm. Analyses under reversed phase and 
normal phase conditions were performed at 25 °C and 35 °C, respectively. Optical rotations 
were obtained on a Jasco P-2000 polarimeter and are reported in deg mL g-1 dm-1; 
concentrations are reported in grams per 100 mL. 
Tris(3,5-dimethyl-1H-pyrazol-1-yl)methane and compounds (S)-1, (S)-2, (S)-7, 22, 14a, (S)-
17 and (S)-18 were prepared as described earlier [19]. Acrylic anhydride was synthesized 
according to the procedure of Jian et al. [24]. Amidine 14g was prepared as reported by 
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Képiró et al. [17]. Compounds 19b and 24 were synthesized according to the procedure of 
Myochin et al. [29]. Pyrrolidinone 21a was prepared as described by Tye et al. [43]. 
Compounds 21d and 28 have been previously prepared by Sedlák et al. [44] and Twibanire et 
al. [45], respectively.  
4.2.2. General procedure for the esterification of phenols using acid chlorides 
In a flame-dried bulb of 50 mL, phenol (0.489 mmol, 1 equiv) was dissolved in 25 mL of dry 
acetonitrile. The reaction mixture was cooled to 0 °C, after which 0.167 g of Cs2CO3 
(0.511 mmol, 1.05 equiv), 0.0119 g of 4-dimethylaminopyridine (0.0973 mmol, 0.2 equiv) 
and acid chloride (0.632 mmol, 1.3 equiv) were added sequentially. Then, the reaction 
mixture was stirred for 30 minutes at room temperature under a nitrogen atmosphere. 
Afterwards, the mixture was evaporated in vacuo, diluted with 150 mL of ethyl acetate and 
washed with saturated aqueous NH4Cl (2× 50 mL). The organic layer was dried over 
magnesium sulfate and evaporated in vacuo.  
4.2.2.1. (S)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)phenyl acrylate ((S)-3) 
(S)-3’-acryloxyblebbistatin (S)-3 was synthesized from (S)-3’-hydroxyblebbistatin (S)-17 
(0.150 g, 0.487 mmol, 1 equiv) and acryloyl chloride (51.5 µL, 0.633 mmol, 1.3 equiv). 
Evaporation in vacuo afforded an orange oil (0.161 g) which was dissolved in 
dichloromethane and coated onto silica under reduced pressure. Subsequently, purification 
was performed via automated flash chromatography with hexane/ethyl acetate as eluent on a 
Reveleris® 12 g silica cartridge (1% sample loading; flow rate: 36 mL min-1; eluent: 2 CV of 
6% ethyl acetate, followed by a gradient from 6% to 60% ethyl acetate over 30 CV; detection 
wavelengths: 220 nm and 270 nm). This resulted in (S)-3’-acryloxyblebbistatin (S)-3 (0.107 g, 
61%) as a yellow powder. The enantiomeric excess was >99% as determined by chiral HPLC 
analysis (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). 
Mp 178 °C. Rf = 0.51 (hexane/ethyl acetate, 1:1). Ee >99%, chiral HPLC: tR ((S)-
3) = 7.63 min, tR ((R)-3) = 8.85 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 
1.0 mL min-1, 25 °C). [α]25D = −295 (c = 0.16 in tetrahydrofuran). 1H NMR (400 MHz, 
DMSO-d6): δ = 2.21–2.36 (5H, m), 3.93–4.10 (2H, m), 6.19 (1H, dd, J1 = 10.2 Hz, 
J2 = 1.1 Hz), 6.46 (1H, dd, J1 = 17.4 Hz, J2 = 10.2 Hz), 6.58 (1H, dd, J1 = 17.4 Hz, 
J2 = 1.1 Hz), 6.89 (1H, s), 6.97 (1H, dd, J1 = 8.1 Hz, J2 = 2.1 Hz), 7.13 (1H, d, J = 8.2 Hz), 
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7.39 (1H, dd, J1 = 8.2 Hz, J2 = 1.6 Hz), 7.48 (1H, dd, J1 = 8.3 Hz, J2 = 8.1 Hz), 7.55 (1H, d, 
J = 1.6 Hz), 7.94 (1H, dd, J1 = 8.3 Hz, J2 = 2.0 Hz), 8.10 (1H, dd, J1 = 2.1 Hz, J2 = 2.0 Hz). 
13C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.6, 48.0, 73.3, 113.3, 117.1, 121.5, 126.5, 
126.8, 128.2, 130.0, 133.1, 134.2, 136.9, 142.0, 149.1, 150.8, 164.6, 165.8, 194.9. IR (ATR, 
cm-1): νmax = 802, 1022, 1146, 1221, 1589, 1692, 1734. MS (ESI): m/z (%) = 362.5 ([M+H]+, 
100). HRMS (ESI): calculated for C21H19N2O4 ([M+H]+) 363.1339; found 363.1345. 
MW = 362.39. 1H NMR spectrum, 13C NMR spectrum and chiral HPLC chromatograms are 
provided in Figures S5–S6 and S44–S45 in the Supporting Information. 
4.2.2.2. (S)-3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-1-
yl)phenyl propionate ((S)-4) 
(S)-3’-propionyloxyblebbistatin (S)-4 was synthesized from (S)-3’-hydroxyblebbistatin (S)-17 
(0.150 g, 0.487 mmol, 1 equiv) and propionyl chloride (59.5 µL, 0.682 mmol, 1.4 equiv). 
Evaporation in vacuo afforded (S)-3’-propionyloxyblebbistatin (S)-4 as a bright yellow 
powder (0.176 g, 99%). The enantiomeric excess was 99% as determined by chiral HPLC 
analysis (Daicel Chiralpak IA column, acetonitrile/water (40:60), 1.0 mL min-1, 25 °C). 
M.p. 176 °C. Rf = 0.53 (hexane/ethyl acetate, 1:1). Ee 99 %, chiral HPLC: tR ((S)-
4) = 16.4 min, tR ((R)-4) = 20.8 min (Daicel Chiralpak IA column, acetonitrile/water (40:60), 
1.0 mL min-1, 25 °C). [α]25D = −290 (c = 0.13 in tetrahydrofuran). 1H NMR (400 MHz, 
DMSO-d6): δ = 1.16 (3H, t, J = 7.5 Hz), 2.21–2.36 (5H, m), 2.65 (2H, q, J = 7.5 Hz), 3.92–
4.10 (2H, m), 6.88 (1H, s), 6.91 (1H, dd, J1 = 8.1 Hz, J2 = 2.0 Hz), 7.14 (1H, d, J = 8.0 Hz), 
7.40 (1H, dd, J1 = 8.0 Hz, J2 = 1.6 Hz), 7.45 (1H, dd, J1 = 8.3 Hz, J2 = 8.1 Hz), 7.55 (1H, d, 
J = 1.6 Hz), 7.90 (1H, dd, J1 = 8.3 Hz, J2 = 1.9 Hz), 8.05 (1H, dd, J1 = 2.0 Hz, J2 = 1.9 Hz). 
13C NMR (100.6 MHz, DMSO-d6): δ = 9.4, 20.7, 27.4, 28.6, 48.0, 73.3, 113.5, 116.9, 117.3, 
121.5, 126.5, 126.8, 129.9, 133.1, 136.9, 142.0, 149.2, 151.1, 165.8, 173.1, 194.9. IR (ATR, 
cm-1): νmax = 791, 1096, 1134, 1593, 1684, 1755, 3420. MS (ESI): m/z (%) = 364.6 ([M+H]+, 
100). HRMS (ESI): calculated for C21H21N2O4 ([M+H]+) 365.1496; found 365.1502. 
MW = 364.40. 1H NMR spectrum, 13C NMR spectrum and chiral HPLC chromatograms are 
provided in Figures S7–S8 and S46–S47 in the Supporting Information. 
4.2.3. General procedure for the amidation of anilines using acid anhydrides 
The selective mono-amidation of anilines was adopted from a publication of Jahani et al. [23].  
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In a bulb of 10 mL containing 3 mL of absolute ethanol, 0.0028 g of guanidine hydrochloride 
(0.0293 mmol, 0.15 equiv), acid anhydride (0.197 mmol, 1.01 equiv) and aniline 
(0.195 mmol, 1 equiv) were brought together under a nitrogen atmosphere. The reaction 
mixture was heated to 40 °C and stirred for 30 minutes. Next, the mixture was diluted with 
75 mL of ethyl acetate and washed with saturated aqueous NaHCO3 (2× 40 mL) and brine 
(30 mL). The organic layer was dried over magnesium sulfate and evaporated in vacuo. 
4.2.3.1. (S)-N-(3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-
1-yl)phenyl)acrylamide ((S)-5) 
(S)-3’-acrylamidoblebbistatin (S)-5 was synthesized from (S)-3’-aminoblebbistatin (S)-18 
(0.0600 g, 0.195 mmol, 1 equiv) and acrylic anhydride (22.7 µL, 0.197 mmol, 1.01 equiv). 
Evaporation in vacuo afforded a yellow powder (0.0670 g) which was dissolved in acetone 
and further purified via preparative TLC with hexane/ethyl acetate (2:3) as eluent. This 
resulted in (S)-3’-acrylamidoblebbistatin (S)-5 (0.0515 g, 73%) as an orange powder. The 
enantiomeric excess was 99% as determined by chiral HPLC analysis (Daicel Chiralpak IA 
column, hexane/dichloromethane/absolute ethanol (10:90:3), 0.5 mL min-1, 35 °C). 
M.p. 236 °C. Rf = 0.21 (hexane/ethyl acetate, 2:3). Ee 99%, chiral HPLC: tR ((S)-
5) = 24.2 min, tR ((R)-5) = 11.1 min (Daicel Chiralpak IA column, 
hexane/dichloromethane/absolute ethanol (10:90:3), 0.5 mL min-1, 35 °C). 1H NMR 
(400 MHz, DMSO-d6): δ = 2.22–2.37, 3.89–3.99, 3.99–4.10, 5.78 (1H, dd, J1 = 10.0 Hz, 
J2 = 1.9 Hz), 6.29 (1H, dd, J1 = 17.0 Hz, J2 = 1.9 Hz), 6.49 (1H, dd, J1 = 17.0 Hz, 
J2 = 10.0 Hz), 6.85 (1H, s), 7.17 (1H, d, J = 7.9 Hz), 7.37 (1H, dd, J1 = 8.2 Hz, J2 = 8.1 Hz), 
7.40 (1H, dd, J1 = 7.9 Hz, J2 = 1.7 Hz), 7.48–7.56 (1H, m), 7.54 (1H, d, J = 1.7 Hz), 7.80 (1H, 
dd, J1 = 8.2 Hz, J2 = 1.8 Hz), 8.43 (1H, dd, J1 = 2.0 Hz, J2 = 1.8 Hz), 10.22 (1H, br. s). 
13C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.8, 48.0, 73.3, 111.3, 115.2, 115.4, 121.5, 
126.5, 126.8, 127.4, 129.4, 132.4, 132.8, 136.9, 139.8, 141.3, 149.5, 163.7, 165.7, 195.0. IR 
(ATR, cm-1): νmax = 781, 797, 1238, 1476, 1589, 1667, 1684. MS (ESI): m/z (%) = 361.5 
([M+H]+, 100). HRMS (ESI): calculated for C21H20N3O3 ([M+H]+) 362.1499; found 
362.1497. MW = 361.39. 1H NMR spectrum, 13C NMR spectrum and chiral HPLC 
chromatograms are provided in Figures S9–S10 and S48–S49 in the Supporting Information. 
4.2.3.2. (S)-N-(3-(3a-hydroxy-6-methyl-4-oxo-2,3,3a,4-tetrahydro-1H-pyrrolo[2,3-b]quinolin-
1-yl)phenyl)propionamide ((S)-6) 
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(S)-3’-propionylamidoblebbistatin (S)-6 was synthesized from (S)-3’-aminoblebbistatin (S)-18 
(0.0600 g, 0.195 mmol, 1 equiv) and propionic anhydride (25.3 µL, 0.197 mmol, 1.01 equiv). 
Evaporation in vacuo afforded (S)-3’-propionylamidoblebbistatin (S)-6 (0.0648 g, 91%) as an 
orange powder. The enantiomeric excess was >99% as determined by chiral HPLC analysis 
(Daicel Chiralpak IA column, hexane/dichloromethane/absolute ethanol (10:90:3), 
0.5 mL min-1, 35 °C). M.p. 220 °C. Ee >99%, chiral HPLC: tR ((S)-6) = 17.4 min, tR ((R)-
6) = 9.37 min (Daicel Chiralpak IA column, hexane/dichloromethane/absolute ethanol 
(10:90:3), 0.5 mL min-1, 35 °C). [α]25D = −306 (c = 0.21 in tetrahydrofuran). 1H NMR 
(400 MHz, DMSO-d6): δ = 1.11 (3H, t, J = 7.5 Hz), 2.22–2.30 (2H, m), 2.31 (3H, s), 2.36 
(2H, q, J = 7.5 Hz), 3.88–3.96 (1H, m), 3.97–4.08 (1H, m), 6.84 (1H, s), 7.16 (1H, d, 
J = 8.1 Hz), 7.32 (1H, t, J = 8.1 Hz), 7.39 (1H, dd, J1 = 8.1 Hz, J2 = 1.9 Hz), 7.41–7.47 (1H, 
m), 7.54 (1H, d, J = 1.9 Hz), 7.74–7.80 (1H, m), 8.33 (1H, t, J = 1.9 Hz), 9.93 (1H, br. s). 
13C NMR (100.6 MHz, DMSO-d6): δ = 10.1, 20.7, 28.8, 30.0, 48.0, 73.3, 110.9, 114.9, 114.9, 
121.5, 126.4, 126.8, 129.2, 132.7, 136.9, 140.2, 141.2, 149.6, 165.7, 172.5, 195.1. IR (ATR, 
cm-1): νmax = 775, 1107, 1238, 1458, 1595, 1622, 1668, 3260, 3341. MS (ESI): 
m/z (%) = 363.5 ([M+H]+, 100). HRMS (ESI): calculated for C21H22N3O3 ([M+H]+) 
364.1656; found 364.1661. MW = 363.41. 1H NMR spectrum, 13C NMR spectrum and chiral 
HPLC chromatograms are provided in Figures S11–S12 and S50–S51 in the Supporting 
Information. 
4.2.4. 1-(4-(Allyloxy)phenyl)pyrrolidin-2-one (21c) 
The N-arylation of 2-pyrrolidinone (20) with aryl iodide 28 was based on Haldón et al. [26]  
In a flame-dried bulb of 250 mL, containing 60 mL of dry 1,4-dioxane, 0.595 g of CuI 
(3.12 mmol, 0.05 equiv) and 0.929 g of tris(3,5-dimethyl-1H-pyrazol-1-yl)methane 
(3.12 mmol, 0.05 equiv) were brought together under a nitrogen atmosphere. Then, 16.2 g of 
aryl iodide 28 (62.3 mmol, 1 equiv), 5.69 mL of 2-pyrrolidinone (20) (74.8 mmol, 1.2 equiv) 
and 26.5 g of K3PO4 (125 mmol, 2 equiv) were added and the reaction mixture was stirred at 
reflux temperature for 24 hours. Next, the suspension was cooled down to room temperature 
and the solids were filtered off on a sintered glass Büchner funnel. The filter cake was rinsed 
with ethyl acetate until the filtrate turned colorless. The filtrate was washed with an equal 
volume of 3 M aqueous HCl (3×) and brine, after which the organic layer was dried over 
magnesium sulfate. Evaporation in vacuo afforded an orange solid (24.2 g) of which 12.1 g 
was dissolved in dichloromethane and coated under reduced pressure onto silica. 
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Subsequently, purification was performed via automated flash chromatography with 
hexane/ethyl acetate as eluent on a Reveleris® 120 g cartridge (10% sample loading; flow 
rate: 80 mL min-1; eluent: 2 CV of 20% ethyl acetate, followed by a gradient from 20% to 
100% ethyl acetate over 20 CV; detection wavelengths: 234 nm and 250 nm). The same 
conditions were applied to purify the other half of the crude mixture. Evaporation of the 
combined fractions resulted in pyrrolidinone 21c (10.2 g, 75%) as a white powder. 
M.p. 104 °C. Rf = 0.16 (hexane/ethyl acetate, 1:1). 1H NMR (400 MHz, CDCl3): δ = 2.15 (2H, 
p, J = 7.6 Hz), 2.59 (2H, t, J = 7.6 Hz), 3.83 (2H, t, J = 7.6 Hz), 4.53 (2H, ddd, J1 = 5.3 Hz, 
J2 = 1.5 Hz, J3 = 1.4 Hz), 5.28 (1H, ddd, J1 = 10.5 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz), 5.41 (1H, dq, 
J1 = 17.3 Hz, J2 = 1.5 Hz), 6.05 (1H, ddt, J1 = 17.3 Hz, J2 = 10.5 Hz, J3 = 5.3 Hz), 6.89–6.94 
(2H, m), 7.46–7.52 (2H, m). 13C NMR (100.6 MHz, CDCl3): δ = 18.1, 32.5, 49.2, 69.1, 115.0, 
117.7, 121.7, 132.8, 133.2, 155.6, 173.9. IR (ATR, cm-1): νmax = 827, 1018, 1225, 1508, 1680. 
MS (ESI): m/z (%) = 218.2 ([M+H]+, 100). HRMS (ESI): calculated for C13H16NO2 ([M+H]+) 
218.1176; found 218.1178. MW = 217.26. 1H NMR and 13C NMR spectra are provided in 
Figures S16–S17 in the Supporting Information. 
4.2.5. General procedure for the N-arylation of 2-pyrrolidinone (20) with aryl bromides 
The N-arylation of 2-pyrrolidinone (20) with aryl bromides was based on a procedure of 
Klapars et al. [28]  
In a flame-dried bulb of 100 mL containing 60 mL of dry 1,4-dioxane, 0.238 g of CuI 
(1.25 mmol, 0.05 equiv) and 269 µL of N,N’-dimethylethylenediamine (2.50 mmol, 
0.1 equiv) were brought together under a nitrogen atmosphere. Then, aryl bromide 
(25.0 mmol, 1 equiv), 2.28 mL of 2-pyrrolidinone (20) (30.0 mmol, 1.2 equiv) and 6.91 g of 
K2CO3 (50.0 mmol, 2 equiv) were added and the reaction mixture was stirred at reflux 
temperature for 23 hours. Next, a second portion of CuI (0.238 g, 1.25 mmol, 0.05 equiv) and 
of N,N’-dimethylethylenediamine (269 µL, 2.50 mmol, 0.1 equiv) were added and the mixture 
was stirred for 8 hours at reflux temperature. The resulting suspension was cooled down to 
room temperature and the solids were filtered off on a sintered glass Büchner funnel. The 
filter cake was rinsed with 150 mL of ethyl acetate. The filtrate was washed with saturated 
aqueous NH4Cl (3× 60 mL) and brine (60 mL), after which the organic layer was dried over 
magnesium sulfate and evaporated in vacuo. 
4.2.5.1. 1-(1-Allylindolin-6-yl)pyrrolidin-2-one (21b) 
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Pyrrolidinone 21b was synthesized from aryl bromide 19b (9.53 g, 40.0 mmol, 1 equiv) and 
2-pyrrolidinone (20) (3.65 mL, 48.0 mmol, 1.2 equiv). Evaporation in vacuo afforded 
pyrrolidinone 21b (9.60 g, 99%) as a yellow-orange oil. 1H NMR (400 MHz, CDCl3): 
δ = 2.12 (2H, p, J = 7.5 Hz), 2.58 (2H, t, J = 7.5 Hz), 2.92 (2H, t, J = 8.3 Hz), 3.36 (2H, t, 
J = 8.3 Hz), 3.72 (2H, ddd, J1 = 6.0 Hz, J2 = 1.4 Hz, J3 = 1.3 Hz), 3.82 (2H, t, J = 7.5 Hz), 
5.19 (1H, ddd, J1 = 10.2 Hz, J2 = 1.5 Hz, J3 = 1.3 Hz), 5.28 (1H, ddd, J1 = 17.1 Hz, 
J2 = 1.5 Hz, J3 = 1.4 Hz), 5.90 (1H, ddt, J1 = 17.1 Hz, J2 = 10.2 Hz, J3 = 6.0 Hz), 6.67 (1H, 
dd, J1 = 7.9 Hz, J2 = 1.9 Hz), 6.92 (1H, d, J = 1.9 Hz), 7.02 (1H, d, J = 7.9 Hz). 13C NMR 
(100.6 MHz, CDCl3): δ = 18.1, 28.0, 32.8, 49.5, 51.8, 53.5, 100.5, 109.4, 117.4, 124.1, 126.9, 
133.9, 139.0, 152.7, 174.0. MS (ESI): m/z (%) = 243.1 ([M+H]+, 100). MW = 242.32. 
1H NMR and 13C NMR spectra are provided in Figures S19–S20 in the Supporting 
Information. 
4.2.6. General procedure for the synthesis of amidines from pyrrolidinones 
The preparation of amidines was adopted from Verhasselt et al. [19].  
A flame-dried bulb of 250 mL, kept under a nitrogen atmosphere, was loaded with 120 mL of 
dry dichloromethane and pyrrolidinone (43.9 mmol, 1 equiv). Next, 8.18 mL of POCl3 
(87.7 mmol, 2 equiv) was added and the resulting mixture was stirred at room temperature for 
24 hours. Afterwards, a solution of methyl 2-amino-5-methylbenzoate (22) (7.61 g, 
46.0 mmol, 1.05 equiv) in dry dichloromethane (45 mL) was added via cannula and the 
reaction mixture was heated to 35 °C for 24 hours. Then, the reaction mixture was cooled to 
0 °C, basified with 3 M aqueous NaOH until the pH equaled 10 and subsequently extracted 
with ethyl acetate (450 mL and 150 mL). The combined organic layers were washed with 
300 mL of brine, dried over magnesium sulfate and evaporated in vacuo. 
4.2.6.1. Methyl 5-methyl-2-((1-(naphthalen-2-yl)pyrrolidin-2-ylidene)amino)benzoate (14d) 
Amidine 14d was synthesized from pyrrolidinone 21a (3.80 g, 18.0 mmol, 1 equiv) and 
methyl 2-amino-5-methylbenzoate (22) (3.12 g, 18.9 mmol, 1.05 equiv). Evaporation in vacuo 
afforded an orange-brown oil (8.54 g) which was dissolved in acetonitrile/dichloromethane 
(1:1) and coated under reduced pressure onto 17.1 g of Davisil® C18 silica. Subsequently, 
purification was performed via automated flash chromatography with water/acetonitrile as 
eluent on a Reveleris® 120 g C18 cartridge (7% sample loading; flow rate: 80 mL min-1; 
eluent: 2 CV of 30% acetonitrile, followed by a gradient from 30% to 80% acetonitrile over 
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20 CV and finally 2 CV of 80% acetonitrile; detection wavelength: 216 nm and 244 nm). 
Evaporation of the combined fractions afforded amidine 14d (3.12 g, 48%) as an off-white 
powder. M.p. 132 °C. 1H NMR (400 MHz, CDCl3): δ = 2.10 (2H, p, J = 7.3 Hz), 2.33 (3H, s), 
2.51 (2H, t, J = 7.3 Hz), 3.84 (3H, s), 3.99 (2H, t, J = 7.3 Hz), 6.74 (1H, d, J = 8.1 Hz), 7.19 
(1H, dd, J1 = 8.1 Hz, J2 = 1.7 Hz), 7.33–7.39 (1H, m), 7.39–7.45 (1H, m), 7.67 (1H, d, 
J = 1.7 Hz), 7.73–7.81 (2H, m), 7.80 (1H, d, J = 9.0 Hz), 7.91 (1H, d, J = 1.8 Hz), 8.31 (1H, 
dd, J1 = 9.0 Hz, J2 = 1.8 Hz). 13C NMR (100.6 MHz, CDCl3): δ = 19.8, 20.6, 29.1, 50.9, 51.8, 
116.4, 121.3, 122.0, 123.1, 124.5, 126.0, 127.4, 127.5, 128.1, 130.1, 131.1, 133.5, 133.8, 
139.4, 150.6, 159.9, 167.8. IR (ATR, cm-1): νmax = 1200, 1304, 1396, 1626, 1653, 1717. MS 
(ESI): m/z (%) = 359.2 ([M+H]+, 100). MW = 358.44. 1H NMR and 13C NMR spectra are 
provided in Figures S22–S23 in the Supporting Information. 
4.2.6.2. Methyl 2-((1-(1-allylindolin-6-yl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (14e) 
Amidine 14e was synthesized from pyrrolidinone 21b (9.59 g, 39.6 mmol, 1 equiv) and 
methyl 2-amino-5-methylbenzoate (22) (6.54 g, 41.6 mmol, 1.05 equiv). Evaporation in vacuo 
afforded a dark red oil (19.5 g) of which 6.50 g was dissolved in dichloromethane and coated 
under reduced pressure onto 13.0 g of Davisil® C18 silica. Subsequently, purification was 
performed via automated flash chromatography with water/acetonitrile as eluent on a 
Reveleris® 120 g C18 cartridge (5% sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 
50% acetonitrile, a gradient from 50% to 60% acetonitrile over 20 CV, a gradient from 60% 
to 100% acetonitrile over 10 CV, and finally 2 CV of 100% acetonitrile; detection 
wavelength: 218 nm and 314 nm). Next, the same conditions were repeated twice to purify the 
remaining parts of the crude mixture. Evaporation of the combined fractions afforded 
amidine 14e (6.49 g, 42%) as an orange oil. Rf = 0.22 (hexane/ethyl acetate, 1:1). 1H NMR 
(400 MHz, CDCl3): δ = 2.00 (2H, p, J = 7.3 Hz), 2.31 (3H, s), 2.44 (2H, t, J = 7.3 Hz), 2.89 
(2H, t, J = 8.2 Hz), 3.32 (2H, t, J = 8.2 Hz), 3.70 (2H, ddd, J1 = 6.1 Hz, J2 = 1.4 Hz, 
J3 = 1.3 Hz), 3.81 (3H, s), 3.82 (2H, t, J = 7.3 Hz), 5.15 (1H, ddd, J1 = 10.4 Hz, J2 = 1.5 Hz, 
J3 = 1.3 Hz), 5.26 (1H, ddd, J1 = 17.0 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz), 5.90 (1H, ddt, 
J1 = 17.0 Hz, J2 = 10.4 Hz, J3 = 6.1 Hz), 6.69 (1H, d, J = 8.1 Hz), 6.88 (1H, dd, J1 = 7.9 Hz, 
J2 = 1.6 Hz), 7.01 (1H, d, J = 7.9 Hz), 7.16 (1H, dd, J1 = 8.1 Hz, J2 = 2.0 Hz), 7.19 (1H, d, 
J = 1.6 Hz), 7.62 (1H, J = 2.0 Hz). 13C NMR (100.6 MHz, CDCl3): δ = 19.9, 20.6, 28.1, 29.1, 
51.4, 51.7, 52.1, 53.6, 101.6, 110.3, 117.2, 122.1, 123.2, 124.0, 125.5, 130.7, 130.9, 133.3, 
134.4, 141.1, 151.0, 152.5, 159.7, 168.0. IR (ATR, cm-1): νmax = 1491, 1501, 1611, 1659, 
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1722. MS (ESI): m/z (%) = 390.2 ([M+H]+, 100). MW = 389.50. 1H NMR and 13C NMR 
spectra are provided in Figures S24–S25 in the Supporting Information. 
4.2.6.3. Methyl 2-((1-(4-(allyloxy)phenyl)pyrrolidin-2-ylidene)amino)-5-methylbenzoate (14f) 
Amidine 14f was synthesized from pyrrolidinone 21c (9.53 g, 43.9 mmol, 1 equiv) and 
methyl 2-amino-5-methylbenzoate (22) (7.61 g, 46.0 mmol, 1.05 equiv). Evaporation in vacuo 
afforded an orange-brown oil (15.5 g) of which 7.75 g was dissolved in 
acetonitrile/dichloromethane (1:1) and coated under reduced pressure onto 15.5 g of Davisil® 
C18 silica. Subsequently, purification was performed via automated flash chromatography 
with water/acetonitrile as eluent on a Reveleris® 120 g C18 cartridge (6% sample loading; 
flow rate: 80 mL min-1; eluent: 2 CV of 30% acetonitrile, followed by a gradient from 30% to 
100% acetonitrile over 20 CV and finally 2 CV of 100% acetonitrile; detection wavelength: 
214 nm). The same conditions were applied to purify the other half of the crude mixture. 
Evaporation of the combined fractions afforded amidine 14f (12.5 g, 78%) as an orange oil. 
Rf = 0.38 (hexane/ethyl acetate/triethylamine, 7:3:0.5). 1H NMR (400 MHz, CDCl3): δ = 2.02 
(2H, p, J = 7.3 Hz), 2.31 (3H, s), 2.43 (2H, t, J = 7.3 Hz), 3.82 (3H, s), 3.82 (2H, t, 
J = 7.3 Hz), 4.51 (2H, ddd, J1 = 5.3 Hz, J2 = 1.5 Hz, J3 = 1.4 Hz), 5.26 (1H, ddd, J1 = 10.5 Hz, 
J2 = 1.5 Hz, J3 = 1.4 Hz), 5.39 (1H, dq, J1 = 17.2 Hz, J2 = 1.5 Hz), 6.04 (1H, ddt, 
J1 = 17.2 Hz, J2 = 10.5 Hz, J3 = 5.3 Hz), 6.70 (1H, d, J = 8.1 Hz), 6.88–6.94 (2H, m), 7.16 
(1H, dd,  J1 = 8.1 Hz, J2 = 1.8 Hz), 7.63 (1H, d, J = 1.8 Hz), 7.66–7.72 (2H, m). 13C NMR 
(100.6 MHz, CDCl3): δ = 19.8, 20.6, 29.0, 51.0, 51.7, 69.1, 114.9, 117.5, 122.1, 122.2, 123.3, 
130.8, 131.0, 133.4, 133.5, 135.0, 150.9, 154.6, 159.8, 167.9. IR (ATR, cm-1): νmax = 1244, 
1404, 1512, 1659, 1722. MS (ESI): m/z (%) = 365.3 ([M+H]+, 100). HRMS (ESI): calculated 
for C22H25N2O3 ([M+H]+) 365.1860; found 365.1868. MW = 364.44. 1H NMR and 13C NMR 
spectra are provided in Figures S26–S27 in the Supporting Information. 
4.2.7. General procedure for the one-pot synthesis of α-hydroxy ketones from amidines 
An oven-dried bulb of 100 mL, degassed and back-filled with argon (5×), was loaded with 
30 mL of dry tetrahydrofuran and 2.15 g of amidine (6.00 mmol, 1 equiv). Then, the solution 
was cooled to −78 °C and 12.6 mL of lithiumbis(trimethylsilyl)amide (1 M solution in 
tetrahydrofuran, 12.6 mmol, 2.1 equiv) was added, after which the mixture was stirred at 0 °C 
for 1.5 hours. Afterwards, the reaction was cooled to −78 °C and a solution of (−)-(8,8-
dichlorocamphorylsulfonyl)oxaziridine (16) (4.29 g, 14.4 mmol, 2.4 equiv) in dry 
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tetrahydrofuran (34 mL) was added via cannula. Subsequently, the mixture was stirred at 
−15 °C for 16 hours before being quenched by the addition of 350 mL of saturated aqueous 
NH4Cl. The reaction mixture was extracted with diethyl ether (3× 440 mL) and the combined 
organic extracts were concentrated to a volume of 220 mL and subsequently washed with 
0.3 M aqueous HCl (3× 240 mL). The combined aqueous layers were washed with 180 mL of 
hexane, basified with 3 M aqueous NaOH until pH 10 was reached and extracted with ethyl 
acetate (2× 1000 mL). The combined organic extracts were dried with magnesium sulfate and 
evaporated in vacuo. 
4.2.7.1. (S)-3a-hydroxy-6-methyl-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-b]quinolin-4-
one ((S)-1) 
(S)-blebbistatin (S)-1 was synthesized from amidine 14a (0.167 g, 0.500 mmol, 1 equiv). 
Evaporation in vacuo afforded (S)-1 (0.146 g, quant) as an ochreous powder. The 
enantiomeric excess was 86% as determined by chiral HPLC analysis (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). 
4.2.7.2. (S)-3a-hydroxy-6-methyl-1-(naphthalen-2-yl)-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-9) 
(S)-benzo[c’]blebbistatin (S)-9 was synthesized from amidine 14d (2.15 g, 6.00 mmol, 
1 equiv). Evaporation in vacuo afforded (S)-9 (1.03 g, 50%) as a yellow powder. The 
enantiomeric excess was 72% as determined by chiral HPLC analysis (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). The powder was redissolved in 
175 mL of boiling acetonitrile and left untouched for 30 minutes at room temperature. This 
resulted in (S)-benzo[c’]blebbistatin (S)-9 (0.546 g, 26%) as bright yellow crystals with an 
enantiomeric excess of >99%. M.p. 246 °C. Ee >99%, chiral HPLC: tR ((S)-9) = 16.6 min, 
tR ((R)-9) = 22.1 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min-1, 
25 °C). [α]25D = −486 (c = 0.10 in tetrahydrofuran). 1H NMR (400 MHz, DMSO-d6): 
δ = 2.27–2.40 (2H, m), 2.33 (3H, s), 4.08–4.24 (2H, m), 6.90 (1H, s), 7.20 (1H, d, J = 8.1 Hz), 
7.41 (1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz), 7.43–7.49 (1H, m), 7.50–7.56 (1H, m), 7.56 (1H, d, 
J = 1.8 Hz), 7.88–7.95 (2H, m), 7.97 (1H, d, J = 9.0 Hz), 8.42 (1H, d, J = 2.1 Hz), 8.51 (1H, 
dd, J1 = 9.0 Hz, J2 = 2.1 Hz). 13C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.8, 48.2, 73.4, 
116.6, 120.4, 121.5, 125.5, 126.5, 126.8, 127.0, 127.9, 128.1, 128.6, 130.2, 132.9, 133.7, 
137.0, 138.9, 149.5, 165.8, 195.0. IR (ATR, cm-1): νmax = 737, 800, 1587, 1605, 1695. MS 
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(ESI): m/z (%) = 343.1 ([M+H]+, 100). HRMS (ESI): calculated for C22H19N2O2 ([M+H]+) 
343.1441; found 343.1451. MW = 342.40. 1H NMR spectrum, 13C NMR spectrum and chiral 
HPLC chromatograms are provided in Figures S29–S30 and S52–S53 in the Supporting 
Information. 
4.2.7.3. (S)-1-(4-(allyloxy)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-12) 
(S)-4’-allyloxyblebbistatin (S)-12 was synthesized from amidine 14f (2.50 g, 6.86 mmol, 
1 equiv). Evaporation in vacuo afforded (S)-12 (1.03 g, 43%) as a bright yellow powder. The 
enantiomeric excess was 82% as determined by chiral HPLC analysis (Daicel Chiralpak IA 
column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). The powder was redissolved in 
9 mL of boiling acetonitrile and left untouched for 7 minutes at room temperature. After 
2 minutes crystals had formed, which were filtered off after an additional 5 minutes. This 
resulted in (S)-4’-allyloxyblebbistatin (S)-12 (0.474 g, 20%) as bright yellow crystals with an 
enantiomeric excess of >99%. M.p. 192 °C. Ee >99%, chiral HPLC: tR ((S)-12) = 13.7 min, 
tR ((R)-12) = 22.5 min (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min-1, 
25 °C). [α]25D = −452 (c = 0.18 in tetrahydrofuran). 1H NMR (400 MHz, DMSO-d6): 
δ = 2.22–2.28 (2H, m), 2.30 (3H, s), 3.88–3.95 (1H, m), 4.00–4.09 (1H, m), 4.59 (2H, ddd, 
J1 = 5.2 Hz, J2 = 1.6 Hz, J3 = 1.5 Hz), 5.28 (1H, ddd, J1 = 10.5 Hz, J2 = 1.6 Hz, J3 = 1.5 Hz), 
5.42 (1H, dq, J1 = 17.3 Hz, J2 = 1.6 Hz), 6.06 (1H, ddt, J1 = 17.3 Hz, J2 = 10.5 Hz, 
J3 = 5.2 Hz), 6.79 (1H, s), 6.99–7.05 (2H, m), 7.07 (1H, d, J = 8.1 Hz), 7.35 (1H, dd,  
J1 = 8.1 Hz, J2 = 2.1 Hz), 7.52 (1H, d, J = 2.1 Hz), 7.94–8.00 (2H, m). 13C NMR (100.6 MHz, 
DMSO-d6): δ = 20.7, 29.0, 48.2, 68.8, 73.4, 115.1, 117.9, 121.4, 121.7, 126.1, 126.8, 132.2, 
134.3, 134.4, 136.9, 150.0, 154.9, 165.3, 195.1. IR (ATR, cm-1): νmax = 800, 827, 937, 995, 
1107, 1595, 1688. MS (ESI): m/z (%) = 349.3 ([M+H]+, 100). HRMS (ESI): calculated for 
C21H21N2O3 ([M+H]+) 349.1547; found 349.1549. MW = 348.40. 1H NMR spectrum, 
13C NMR spectrum and chiral HPLC chromatograms are provided in Figures S31–S32 and 
S54–S55 in the Supporting Information. 
4.2.7.4. (S)-3a-hydroxy-6-methyl-1-(4-nitrophenyl)-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-29) [17]  
(S)-4’-nitroblebbistatin (S)-29 was synthesized from amidine 14g (1.15 g, 3.25 mmol, 
1 equiv). Evaporation in vacuo afforded an orange oil (1.09 g), containing 40 m% of (S)-4’-
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nitroblebbistatin (S)-29 and 60 m% of dimer 30, which was dissolved in tetrahydrofuran and 
coated under reduced pressure onto silica. Subsequently, purification was performed via 
automated flash chromatography with hexane/ethyl acetate as eluent on a Reveleris® 120 g 
silica cartridge (1% sample loading; flow rate: 80 mL min-1; eluent: 2 CV of 0% ethyl acetate, 
followed by a gradient from 0% to 40% ethyl acetate over 30 CV; detection wavelengths: 
260 nm and 368 nm). This resulted in (S)-4’-nitroblebbistatin (S)-29 (0.416 g, 38%) as an 
orange powder. The enantiomeric excess was 82% as determined by chiral HPLC analysis 
analysis (Daicel Chiralpak IA column, acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). The 
powder was redissolved in 25 mL of boiling acetonitrile and left untouched for 19 hours at 
room temperature. This resulted in (S)-4’-nitroblebbistatin (S)-29 (0.248 g, 20%) as orange 
crystals with an enantiomeric excess of >99%. Rf = 0.32 (hexane/ethyl acetate, 1:1). Ee >99%, 
chiral HPLC: tR ((S)-29) = 16.6 min, tR ((R)-29) = 32.1 min (Daicel Chiralpak IA column, 
acetonitrile/water (50:50), 1.0 mL min-1, 25 °C). 1H NMR (400 MHz, DMSO-d6): δ = 2.25–
2.40 (2H, m), 2.34 (3H, s), 4.03–4.15 (2H, m), 6.97 (1H, s), 7.24 (1H, d, J = 8.1 Hz), 7.45 
(1H, dd, J1 = 8.1 Hz, J2 = 1.8 Hz), 7.59 (1H, d, J = 1.8 Hz), 8.28–8.34 (2H, m), 8.36–8.42 
(2H, m). MW = 337.34. 1H NMR spectrum and chiral HPLC chromatograms are provided in 
Figures S33 and S56–S57 in the Supporting Information. 
4.2.8. (S)-3a-hydroxy-1-(indolin-6-yl)-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-8) 
Amidine 14e (2.64 g, 6.77 mmol, 1 equiv) was converted via the general procedure for the 
one-pot synthesis of α-hydroxy ketones from amidines. Evaporation in vacuo afforded an 
orange-brown powder (1.29 g), containing 86% (m/m) of compound (S)-25 and 14% (m/m) of 
molecule (S)-26. The enantiomeric excess of (S)-25 in this mixture was 80% as determined by 
chiral HPLC analysis (Daicel Chiralpak IA column, acetonitrile/water (60:40), 1.0 mL min-1, 
25 °C). The powder was redissolved in 50 mL of boiling absolute ethanol and left untouched 
for 19 hours at room temperature. This afforded dark yellow-brown fibers (0.212 g), 
containing 91% (m/m) of (S)-25 and 9% (m/m) of (S)-26, with an enantiomeric excess of 
>99%. Chiral HPLC chromatograms are provided in Figures S57–S58 in the Supporting 
Information. 
In a flame-dried bulb of 50 mL containing 15 mL of dry dichloromethane, 0.210 g of the (S)-
25/(S)-26 (91:9) mixture (0.512 mmol of (S)-25, 1 equiv), 0.479 g of N,N’-dimethylbarbituric 
acid (3.07 mmol, 6 equiv) and 0.0590 g of tetrakis(triphenylphosphine)palladium(0) 
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(0.0512 mmol, 0.1 equiv) were brought together under a nitrogen atmosphere and stirred for 1 
hour at reflux temperature. Afterwards, the reaction mixture was cooled to room temperature, 
diluted with 90 mL of ethyl acetate and washed with saturated aqueous NaHCO3 (2× 30 mL). 
The organic layer was dried over magnesium sulfate and evaporated in vacuo. This resulted in 
an orange-brown powder (0.354 g) which was dissolved in tetrahydrofuran and coated under 
reduced pressure onto silica. Subsequently, purification was performed via automated flash 
chromatography with hexane/ethyl acetate as eluent on a Reveleris® 40 g silica cartridge (1% 
sample loading; flow rate: 40 mL min-1; eluent: 2 CV of 20% ethyl acetate, followed by a 
gradient from 20% to 100% ethyl acetate over 20 CV; detection wavelengths: 220 nm and 
250 nm). This resulted in (S)-2,3-dihydro-1H-pyrrolo[2,3-c’]blebbistatin (S)-8 (0.125 g, 73%) 
as an orange powder. The enantiomeric excess was >99% as determined by chiral HPLC 
analysis analysis (Daicel Chiralpak IA column, acetonitrile/water (60:40), 1.0 mL min-1, 
25 °C). Rf = 0.22 (hexane/ethyl acetate, 1:1). Ee >99%, chiral HPLC: tR ((S)-8) = 4.93 min, 
tR ((R)-8) = 8.19 min (Daicel Chiralpak IA column, acetonitrile/water (60:40), 1.0 mL min-1, 
25 °C). 1H NMR (400 MHz, DMSO-d6): δ = 2.18–2.25 (2H, m), 2.29 (3H, s), 2.90 (2H, t, 
J = 8.4 Hz), 3.44 (2H, t, J = 8.4 Hz), 3.82–3.89 (2H, m), 3.95–4.04 (2H, m), 5.64 (1H, br. s), 
6.78 (1H, s), 7.00–7.06 (1H, m), 7.03–7.07 (2H, m), 7.33–7.38 (1H, m), 7.36–7.38 (1H, m), 
7.51 (1H, d, J = 1.8 Hz). 13C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 28.9, 29.2, 47.2, 48.5, 
73.5, 101.5, 109.2, 121.3, 124.3, 125.1, 126.1, 126.7, 132.2, 136.9, 140.3, 150.1, 153.4, 165.5, 
195.2. IR (ATR, cm-1): νmax = 1229, 1479, 1582, 1599, 1692. MS (ESI): m/z (%) = 334.1 
([M+H]+, 100). HRMS (ESI): calculated for C20H20N3O2 ([M+H]+) 334.1550; found 
334.1554. MW = 333.39. 1H NMR spectrum, 13C NMR spectrum and chiral HPLC 
chromatograms are provided in Figures S34–S35 and S60–S61 in the Supporting Information. 
4.2.9. (S)-3a-hydroxy-1-(1H-indol-6-yl)-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-10) 
Oxidation of (S)-2,3-dihydro-1H-pyrrolo[2,3-c’]blebbistatin (S)-8 to (S)-1H-pyrrolo[2,3-
c’]blebbistatin (S)-10 was based on a procedure reported by Reggelin et al. [46]  
In a bulb of 50 mL, 0.105 g of (S)-8 (0.316 mmol, 1 equiv) was dissolved in 40 mL of 
chloroform, after which 0.312 g of MnO2 (88%) (3.16 mmol, 10 equiv) was added, and the 
mixture was stirred for 3 hours at room temperature. Next, the solids were filtered off over 
celite and the filter cake was rinsed with 120 mL of tetrahydrofuran. Evaporation of the 
filtrate in vacuo afforded (S)-1H-pyrrolo[2,3-c’]blebbistatin (S)-10 (0.0729 g, 70%) as an 
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orange powder. The enantiomeric excess was >99% as determined by chiral HPLC analysis 
analysis (Daicel Chiralpak IA column, acetonitrile/water (60:40), 1.0 mL min-1, 25 °C). M.p. 
233 °C. Ee >99%, chiral HPLC: tR ((S)-10) = 4.52 min, tR ((R)-10) = 5.94 min (Daicel 
Chiralpak IA column, acetonitrile/water (60:40), 1.0 mL min-1, 25 °C). [α]25D = −578 
(c = 0.10 in tetrahydrofuran). 1H NMR (400 MHz, DMSO-d6): δ = 2.23–2.34 (2H, m, 2.30 
(3H, s), 3.94–4.04 (2H, m), 4.10–4.21 (2H, m), 6.40–6.45 (1H, m), 6.81 (1H, s), 7.07 (1H, d, 
J = 8.1 Hz), 7.32–7.37 (1H, m), 7.33–7.40 (1H, m), 7.50–7.55 (1H, m), 7.50–7.55 (1H, m), 
8.23 (1H, br. s), 11.14 (1H, br. s). 13C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 29.2, 49.0, 
73.6, 101.4, 104.6, 113.2, 120.2, 121.4, 125.0, 126.0, 126.3, 126.8, 131.9, 135.1, 136.2, 136.9, 
150.4, 165.6, 195.3. IR (ATR, cm-1): νmax = 799, 833, 1476, 1595, 1678, 3244, 3402. MS 
(ESI): m/z (%) = 332.1 ([M+H]+, 100). HRMS (ESI): calculated for C20H18N3O2 ([M+H]+) 
332.1394; found 332.1396. MW = 331.38. 1H NMR spectrum, 13C NMR spectrum and chiral 
HPLC chromatograms are provided in Figures S36–S37 and S62–S63 in the Supporting 
Information. 
4.2.10. (S)-3a-hydroxy-1-(4-hydroxyphenyl)-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-11) 
The deprotection of (S)-4’-allyloxyblebbistatin (S)-12 to afford (S)-4’-hydroxyblebbistatin 
(S)-11 was based on a publication of Vutukuri et al. [47]  
In a flame-dried bulb of 100 mL, containing 40 mL of dry methanol, 0.294 g of (S)-4’-
allyloxyblebbistatin (S)-12 (0.842 mmol, 1 equiv) and 0.485 g of 
tetrakis(triphenylphosphine)palladium(0) (0.0421 mmol, 0.05 equiv) were brought together 
under a nitrogen atmosphere and stirred for 5 minutes at room temperature. Then, 0.698 g of 
K2CO3 (5.05 mmol, 6 equiv) was added and the reaction mixture was stirred for 1.5 hours at 
50 °C. Afterwards, the mixture was concentrated to a volume of 5 mL, diluted with 80 mL of 
ethyl acetate, washed with saturated aqueous NH4Cl (2× 15 mL) and dried over magnesium 
sulfate. Evaporation in vacuo afforded bright orange fibers (0.372 g) which were dissolved in 
tetrahydrofuran and coated under reduced pressure onto silica. Subsequently, purification was 
performed via automated flash chromatography with hexane/ethyl acetate as eluent on a 
Reveleris® 40 g silica cartridge (1% sample loading; flow rate: 40 mL min-1; eluent: 2 CV of 
16% ethyl acetate, followed by a gradient from 16% to 70% ethyl acetate over 25 CV; 
detection wavelengths: 220 nm and 262 nm). This resulted in (S)-4’-hydroxyblebbistatin (S)-
11 (0.201 g, 77%) as a bright orange powder. The enantiomeric excess was >99% as 
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determined by chiral HPLC analysis of (S)-4’-benzyloxyblebbistatin (S)-13. M.p. 224 °C. 
Rf = 0.30 (hexane/ethyl acetate, 7:13). Ee >99%. [α]25D = −473 (c = 0.13 in tetrahydrofuran). 
1H NMR (400 MHz, CD3OD): δ = 2.31–2.39 (2H, m), 2.33 (3H, s), 3.87–3.95 (1H, m), 4.09–
4.17 (1H, m), 6.84–6.90 (2H, m), 7.08 (1H, d, J = 8.2 Hz), 7.33 (1H, dd, J1 = 8.2 Hz, 
J2 = 2.2 Hz), 7.54–7.60 (2H, m), 7.62 (1H, d, J = 2.2 Hz). 13C NMR (100.6 MHz, CD3OD): 
δ = 19.2, 29.0, 49.5, 73.4, 115.2, 120.8, 124.0, 124.9, 126.5, 131.7, 132.2, 136.5, 149.7, 155.2, 
166.0, 195.2. IR (ATR, cm-1): νmax = 804, 1209, 1476, 1584, 1597, 1665, 3210, 3591. MS 
(ESI): m/z (%) = 309.2 ([M+H]+, 100). HRMS (ESI): calculated for C18H17N2O3 ([M+H]+) 
309.1234; found 309.1234. MW = 308.33. 1H NMR and 13C NMR spectra are provided in 
Figures S38–S39 in the Supporting Information. 
4.2.11. (S)-1-(4-(benzyloxy)phenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-
pyrrolo[2,3-b]quinolin-4-one ((S)-13) 
In a flame-dried bulb of 10 mL, 0.0300 g of (S)-4’-hydroxyblebbistatin (S)-11 (0.0973 mmol, 
1 equiv) was dissolved in 5 mL of dry acetonitrile. The reaction mixture was cooled to 0 °C, 
after which 0.0015 g of NaI (0.0097 mmol, 0.1 equiv), 0.0333 g of Cs2CO3 (0.102 mmol, 
1.05 equiv) and 12.1 µL of benzyl bromide (0.102 mmol, 1.05 equiv) were added 
sequentially. Then, the reaction mixture was stirred for 1 hour at 50 °C under a nitrogen 
atmosphere. Afterwards, the mixture was diluted with 30 mL of ethyl acetate and washed with 
saturated aqueous NH4Cl (2× 10 mL). The organic layer was dried over magnesium sulfate 
and evaporated in vacuo. This resulted in a yellow-orange powder (0.0475 g) which was 
dissolved in tetrahydrofuran and coated under reduced pressure onto silica. Subsequently, 
purification was performed via automated flash chromatography with hexane/ethyl acetate as 
eluent on a Reveleris® 12 g silica cartridge (1% sample loading; flow rate: 30 mL min-1; 
eluent: 2 CV of 10% ethyl acetate, followed by a gradient from 10% to 70% ethyl acetate over 
30 CV; detection wavelengths: 228 nm and 268 nm). This resulted in (S)-4’-
benzyloxyblebbistatin (S)-13 (0.0242 g, 62%) as a yellow powder. The enantiomeric excess 
was >99% as determined by chiral HPLC analysis analysis (Daicel Chiralpak IA column, 
acetonitrile/water (70:30), 1.0 mL min-1, 25 °C). Rf = 0.32 (hexane/ethyl acetate, 3:2). 
Ee >99%, chiral HPLC: tR ((S)-13) = 6.80 min, tR ((R)-13) = 9.55 min (Daicel Chiralpak IA 
column, acetonitrile/water (70:30), 1.0 mL min-1, 25 °C). 1H NMR (400 MHz, DMSO-d6): 
δ = 2.21–2.28 (2H, m), 2.30 (3H, s), 3.87–3.95 (1H, m), 4.00–4.09 (1H, m), 5.13 (2H, s), 6.79 
(1H, s), 7.05–7.11 (3H, m), 7.31–7.38 (2H, m), 7.38–7.44 (2H, m), 7.45–7.49 (2H, m), 7.52 
(1H, d, J = 1.6 Hz), 7.94–8.00 (2H, m). 13C NMR (100.6 MHz, DMSO-d6): δ = 20.7, 29.0, 
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48.2, 69.8, 73.4, 115.3, 121.4, 121.7, 126.1, 126.8, 128.2, 128.3, 128.9, 132.2, 134.5, 136.9, 
137.6, 150.0, 155.0, 165.3, 195.1. IR (ATR, cm-1): νmax = 733, 1236, 1481, 1510, 1597, 1692. 
MS (ESI): m/z (%) = 399.2 ([M+H]+, 100). HRMS (ESI): calculated for C25H23N2O3 
([M+H]+) 399.1703; found 399.1713. MW = 398.45. 1H NMR spectrum, 13C NMR spectrum 
and chiral HPLC chromatograms are provided in Figures S40–S41 and S64–S65 in the 
Supporting Information. 
4.2.12. (S)-1-(4-aminophenyl)-3a-hydroxy-6-methyl-1,2,3,3a-tetrahydro-4H-pyrrolo[2,3-
b]quinolin-4-one ((S)-31) [18]  
In each of seven vials of 3 mL, 5.0 mg of (S)-29 (0.015 mmol, 1 equiv) was dissolved in 2 mL 
of methanol, after which 9.4 mg of ammonium formate (0.148 mmol, 10 equiv) and 5.0 mg of 
10% Pd/C were added. The mixture was stirred for 15 minutes at room temperature. Next, the 
contents of all seven vials were filtered off over celite and the filter cake was rinsed with 
20 mL of methanol. Afterwards, the filtrate was concentrated to a volume of 5 mL, diluted 
with 70 mL of ethyl acetate, washed with saturated aqueous NH4Cl (2× 30 mL) and dried 
over magnesium sulfate. Evaporation in vacuo afforded a dark orange powder (0.039 g) which 
was dissolved in tetrahydrofuran and coated under reduced pressure onto silica. Subsequently, 
purification was performed via automated flash chromatography with hexane/ethyl acetate as 
eluent on a Reveleris® 12 g silica cartridge (0.3% sample loading; flow rate: 36 mL min-1; 
eluent: 2 CV of 20% ethyl acetate, followed by a gradient from 20% to 100% ethyl acetate 
over 20 CV; detection wavelengths: 246 nm and 260 nm). This resulted in (S)-4’-
aminoblebbistatin (S)-31 (9.8 mg, 31%) as a bright red powder. Rf = 0.25 (hexane/ethyl 
acetate, 1:4). 1H NMR (400 MHz, DMSO-d6): δ = 2.17–2.24 (2H, m), 2.28 (3H, s), 3.77–3.89 
(1H, m), 3.94–4.04 (1H, m), 6.71 (1H, s), 6.57–6.64 (2H, m), 7.01 (1H, d, J = 8.2 Hz), 7.31 
(1H, dd, J1 = 8.1 Hz, J2 = 1.7 Hz), 7.48 (1H, d, J = 1.7 Hz), 7.62–7.67 (2H, m). 13C NMR 
(100.6 MHz, DMSO-d6): δ = 20.6, 29.1, 48.4, 73.5, 114.1, 121.2, 122.1, 126.0, 126.7, 130.2, 
131.5, 136.9, 146.0, 150.7, 165.0, 195.3. IR (ATR, cm-1): νmax = 833, 1263, 1477, 1508, 1593, 
1674, 3347, 3445, 3499.  MS (ESI): m/z (%) = 308.0 ([M+H]+, 100). HRMS (ESI): calculated 
for C18H18N3O2 ([M+H]+) 308.1394; found 308.1390. MW = 307.35. 1H NMR and 13C NMR 
spectra are provided in Figures S42–S43 in the Supporting Information. 
4.3. ATPase assay 
4.3.1. Preparation of F-actin filaments stock solution 
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Pre-formed rabbit skeletal muscle F-actin filaments (cat. # AKF99) were purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The protein was dissolved in 2.4 mL of Milli-Q 
water and gently mixed to a concentration of 0.4 mg mL-1. To allow filaments to dissociate 
from each other, this solution was incubated at room temperature for 10 minutes. Then, the 
filaments were aliquoted into 100 µL samples, snap frozen in liquid nitrogen and stored at 
−80 °C. For compounds (S)-2–7, (S)-8–13 and (S)-29,31, different batches of pre-formed 
rabbit skeletal muscle F-actin filaments were used. As a reference, compound (S)-1 was 
evaluated with all batches of pre-formed rabbit skeletal muscle F-actin filaments. 
4.3.2. Preparation of myosin stock solution 
Full-length rabbit skeletal muscle myosin II protein (cat. # MY02) was purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The protein was dissolved in 100 µL of Milli-Q 
water containing 1 mM DTT and incubated on ice for 5 minutes to completely solubilize it to 
a concentration of 10 mg mL-1. Care should be taken not to vortex the solution, in order to 
avoid protein denaturation caused by shear stress. Then, the myosin solution was further 
aliquoted into 10 µL samples, snap frozen in liquid nitrogen and stored at −80 °C. For 
compounds (S)-2–7, (S)-8–13 and (S)-29,31, different batches of full-length rabbit skeletal 
muscle myosin II protein were used. As a reference, compound (S)-1 was evaluated with all 
batches of full-length rabbit skeletal muscle myosin II protein. 
4.3.3. Preparation of ATP stock solution 
Adenosine 5’-triphosphate disodium salt (ATP, cat. # BSA04) was purchased from 
Cytoskeleton, Inc. in lyophilized form (1 mg). The ATP was reconstituted to 100 mM with 
1 mL of ice-cold 100 mM Tris-HCl pH 7.5 and then aliquoted into 10 µL samples, snap 
frozen in liquid nitrogen and stored at −20 °C. For compounds (S)-2–7, (S)-8–13 and (S)-
29,31, different batches of adenosine 5’-triphosphate disodium salt were used. As a reference, 
compound (S)-1 was evaluated with all batches of adenosine 5’-triphosphate disodium salt. 
4.3.4. ATPase assay 
Screening for inhibitors of rabbit skeletal muscle myosin II ATPase was performed in an 
ATPase end-point assay adapted from the method of Kodama et al. [48]. Incubation times and 
relative amounts of F-actin, myosin and ATP were determined based on a publication of 
Cheung et al. [49].  As the linear range for inorganic phosphate detection of the assay extends 
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from approximately 0.1 nmol to 1.5 nmol of inorganic phosphate, a total amount of 1.6 nmol 
ATP was used [50]. 
Prior to each assay, aliquoted samples of F-actin, myosin and ATP were defrosted rapidly in a 
37 °C water bath and further dilutions were made: myosin was diluted to 33 µg mL-1 with ice-
cold reaction buffer (15 mM Tris-HCl pH 7.5, 25 mM KCl, 10 mM MgCl2, 0.1 mM EGTA) 
and stored on ice, ATP was diluted to 0.04 mM with ice-cold 15 mM Tris-HCl pH 7.5 and 
stored on ice, F-actin was diluted to 133 µg mL-1 with reaction buffer and stored at room 
temperature.  
Chemical compounds dissolved in DMSO (1 µL) were transferred into each well of a 96-well 
plate. Then, 15 µL of reaction buffer, 15 µL of 133 µg mL-1 F-actin and 15 µL of 33 µg mL-1 
myosin were subsequently distributed in each well using a multichannel pipette. Afterwards, 
the ATP hydrolysis reaction was initiated by adding 15 µL of 0.04 mM ATP per well using a 
multichannel pipette and was then incubated for 1 hour at 37 °C. To measure the amount of 
inorganic phosphate (Pi) generated during the enzymatic hydrolysis of ATP, 139 µL of 
development solution (CytoPhos™ reagent, cat. # BK054 from Cytoskeleton) was added to 
each well using a multichannel pipette. After 20 minutes, the absorbance at 650 nm was 
measured in each assay well using a SpectraMax® Paradigm® Multi-Mode Microplate Reader. 
On each assay plate, two concentrations of (S)-1 (2.25 µM or 1 µM for (S)-2–7 and (S)-8–
13,29,31, respectively, and 32.5 µM) were included as a positive control and the resulting 
amount of inhibition was comparable over the different assay plates. All screenings were 
carried out twice (N = 2).  
4.3.5. IC50 determination 
Data points representing the mean ± s.d. of at least three samples, were plotted on semi-log 
axes and a 4-parameter logistic curve, based on the following equation, was fitted to the 
means. 
  y = A + 
B - A
1 + xC
D  
Here, y represents the actin-activated ATPase activity of rabbit skeletal muscle myosin II (%) 
and x corresponds to the compound concentration (µM). A is the ATPase activity 
corresponding to the asymptote at high compound concentrations (%), B is the ATPase 
activity corresponding to the asymptote at low compound concentrations (%), C represents the 
compound concentration corresponding to the midpoint between A and B (µM) (i.e. IC50 
41 
 
value) and D describes how rapidly the curve makes its transition from the asymptotes in the 
center of the curve.  
4.4. Determination of photostability 
4.4.1. 450 W Xenon Lamp light source 
(S)-blebbistatin (S)-1 was dissolved in methanol and further diluted with phosphate-buffered 
saline (PBS) to obtain a final concentration of 20 µM. The amount of methanol was 
maintained at a constant concentration of 2.67% (v/v) in all samples. A different sample was 
used for each irradiation time. Irradiation at 488 nm (excitation slit width = 10 nm) was 
performed using an Edingburgh Instruments F900 Fluorescence Spectrometer equipped with a 
450 W Xenon Lamp. Afterwards, UV-VIS absorption spectra were recorded for all samples 
using a Varian Cary 50 spectrophotometer. All absorption spectra were corrected for the 
solvent mixture by subtracting the absorption spectrum of the solvent blank. 
4.4.2. TL 140W/03 light source 
Stock solutions of chemical compounds were prepared in DMSO (Figure 4B, Figure S3), 
DMSO/H2O (1:1) (Figures 4B–C, Figure S3, Figure S4) or a 1:1 mixture of DMSO and 
DMEM supplemented with 20% (v/v) fetal calf serum (Figure 4D, Figure 5). Then, 200 µL of 
each stock solution was transferred into the wells of 96-well plates. Separate wells were used 
for different irradiation times, so each well corresponded to one compound and one irradiation 
time. The solutions were irradiated for 0–90 min by placing the 96-well plates (covered with 
an evaporation lid) on top of two luminescent tubes (TL 140W/03, Philips, Special Lighting, 
Belgium) emitting 390–470 nm with a maximum at 420 nm, using holders of 6 cm height 
(Figures S2 in the Supporting Information). On each 96-well plate, two columns could be 
irradiated with one luminescent tube. After the appropriate illumination time, 200 µL (i.e. the 
total content) of each well was analyzed by HPLC as such: the absolute peak area of the 
compound under study was quantified and compared with that at the start of the experiment. 
The relative amount of compound (%) was plotted in function of irradiation time (min) on 
semi-log axes and a 4-parameter logistic curve, based on the following equation, was fitted to 
the data points. 
  y = A + 
B - A
1 + xC
D  
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Here, y represents the relative amount of compound (%) and x corresponds to the irradiation 
time (min). A is the relative amount of compound corresponding to the asymptote at high 
irradiation times (%), B is the relative amount of compound corresponding to the asymptote at 
low irradiation times (%), C represents the irradiation time corresponding to the midpoint 
between A and B (min) and D describes how rapidly the curve makes its transition from the 
asymptotes in the center of the curve. Finally, the compound half-life (min) was determined 
by solving the equation above for y = 50%. 
4.5. Determination of steady-state aqueous solubility 
The steady-state aqueous solubility was determined by Eurofins Panlabs. 
Compounds were added to a PBS pH 7.4 buffer as a 10 mM dimethyl sulfoxide (DMSO) 
solution and were incubated at room temperature while agitating the suspension. DMSO and 
compound concentrations were 2% (v/v) and 200 µM, respectively. After 24 hours, the 
suspension was centrifuged and filtered through a 0.2 µM filter membrane. Compound 
concentrations in the buffer sample were determined by HPLC. Absorption spectra (230 nm) 
were recorded and the concentration of the dissolved compound was determined by 
comparing the peak area of the principal peak in the buffer sample with the peak area of the 
corresponding peak in a calibration standard (200 µM) containing organic solvent 
(methanol/water (60:40)). The experiments were performed in duplicate. 
4.6. Determination of Caco-2 cell membrane permeability 
Caco-2 cell membrane permeability was determined by Eurofins Panlabs. 
In short, Caco-2 cells were cultured on 96-well polycarbonate membrane filters and the 
apparent permeability (Papp) of test compounds were determined in the apical-to-basolateral 
(A-B) and basolateral-to-apical (B-A) directions across the Caco-2 cell monolayer. 
Compounds were prepared at 10 µM in HBSS-HEPES buffer, pH 7.4 (with a final DMSO 
concentration of 1% (v/v)) and added to the apical side (for A-B permeability) or basolateral 
side (for B-A permeability). The same buffer without compound was added to the basolateral 
side (for A-B permeability) or apical side (for B-A permeability). The assay plates were 
incubated at 37 °C with gentle shaking for 60 minutes (for A-B permeability) or 40 minutes 
(for B-A permeability). Samples were taken from the donor side at the start and from the 
donor and receiver sides at the end of the incubation and analyzed by HPLC-MS/MS. The 
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apparent permeability (Papp) was calculated based on the appearance rate of compound in the 
receiver side. In addition, recovery of the test compound was determined as the relative 
amount of compound detected in both the receiver and the donor sides at the end of the assay 
to the amount detected in the donor side at the start. The experiments were performed in 
duplicate. 
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